



(12) **DEMANDE DE BREVET CANADIEN
CANADIAN PATENT APPLICATION**


(13) **A1**

(86) Date de dépôt PCT/PCT Filing Date: 2019/04/17
 (87) Date publication PCT/PCT Publication Date: 2019/10/24
 (85) Entrée phase nationale/National Entry: 2020/09/23
 (86) N° demande PCT/PCT Application No.: EP 2019/060007
 (87) N° publication PCT/PCT Publication No.: 2019/202040
 (30) Priorité/Priority: 2018/04/18 (EP18168011.7)

(51) Cl.Int./Int.Cl. *C07K 16/28* (2006.01)
 (71) Demandeur/Applicant:
 F. HOFFMANN-LA ROCHE AG, CH
 (72) Inventeurs/Inventors:
 DENGL, STEFAN, DE;
 FENN, SEBASTIAN, DE;
 FISCHER, JENS, DE;
 HINZ, ANDREAS, DE;
 KIRSTENPFAD, CLAUDIA, DE;
 KLOSTERMANN, STEFAN, DE;
 MOELLEKEN, JOERG, DE;
 ...
 (74) Agent: GOWLING WLG (CANADA) LLP

(54) Titre : ANTICORPS ANTI-HLA-G ET LEUR UTILISATION
 (54) Title: ANTI-HLA-G ANTIBODIES AND USE THEREOF

Fig. 3A



(57) **Abrégé/Abstract:**

The present invention relates to anti-HLA-G antibodies and methods of using the same.

(72) **Inventeurs(suite)/Inventors(continued):** TIEFENTHALER, GEORG, DE; HOVES, SABINE, DE;
BUJOTZEK, ALEXANDER, DE; MAJETY, MEHER, DE

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau(10) International Publication Number
WO 2019/202040 A1(43) International Publication Date
24 October 2019 (24.10.2019)(51) International Patent Classification:
C07K 16/28 (2006.01)(21) International Application Number:
PCT/EP2019/060007(22) International Filing Date:
17 April 2019 (17.04.2019)

(25) Filing Language: English


(26) Publication Language: English

(30) Priority Data:
18168011.7 18 April 2018 (18.04.2018) EP(71) Applicant (for all designated States except US): **F. HOFFMANN-LA ROCHE AG** [CH/CH]; Grenzacherstrasse 124, 4070 Basel (CH).(71) Applicant (for US only): **HOFFMANN-LA ROCHE INC.** [US/US]; Great Notch, 150 Clove Road 8th Floor, Suite 8 - Legal Department, Little Falls, New Jersey 07424 (US).(72) Inventors: **DENGL, Stefan**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **FENN, Sebastian**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **FISCHER, Jens**; c/o Roche DiagnosticsGmbH Nonnenwald 2, 82377 Penzberg (DE). **HINZ, Andreas**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **KIRSTENPFAD, Claudia**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **KLOSTERMANN, Stefan**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **MOELLEKEN, Joerg**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **TIEFENTHALER, Georg**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **HOVES, Sabine**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **BUJOTZEK, Alexander**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE). **MAJETY, Meher**; c/o Roche Diagnostics GmbH Nonnenwald 2, 82377 Penzberg (DE).(74) Agent: **JENNI, Wolfgang**; Roche Diagnostics GmbH Patent Department (LPP.....6164), 82372 Penzberg (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,

(54) Title: ANTI-HLA-G ANTIBODIES AND USE THEREOF

Fig. 3A



(57) Abstract: The present invention relates to anti-HLA-G antibodies and methods of using the same.

WO 2019/202040 A1 

OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *of inventorship (Rule 4.17(iv))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*

Anti-HLA-G antibodies and use thereof

The present invention relates to anti-HLA-G antibodies, their preparation, formulations and methods of using the same.

Background of the Invention

5 The human major histocompatibility complex, class I, 6, also known as human leukocyte antigen G (HLA-G), is a protein that in humans is encoded by the HLA-G gene. HLA-G belongs to the HLA nonclassical class I heavy chain paralogues. This class I molecule is a heterodimer consisting of a heavy chain and a light chain (beta-2 microglobulin). The heavy chain is anchored in the membrane but can also be shedded/secreted.

- 10
- The heavy chain consists of three domains: alpha 1, alpha 2 and alpha 3. The alpha 1 and alpha 2 domains form a peptide binding groove flanked by two alpha helices. Small peptides (approximately 9-mers) can bind to this groove akin to other MHC I proteins.
 - The second chain is beta 2 microglobulin which binds to the heavy chain
- 15 similar to other MHC I proteins.

For HLA-G there exist 7 isoforms, 3 secreted and 4 membrane bound forms (as schematically shown in Fig.1).

20 HLA-G can form functionally active complex oligomeric structures (Kuroki, K et al. Eur J Immunol. 37 (2007) 1727–1729). Disulfide-linked dimers are formed between Cys 42 of two HLA-G molecules. (Shiroishi M et al., J Biol Chem 281 (2006) 10439-10447. Trimers and Tetrameric complexes have also been described e.g. in Kuroki, K et al. Eur J Immunol. 37 (2007) 1727–1729, Allan D.S., et al. J Immunol Methods. 268 (2002) 43-50 and T Gonen-Gross et al., J Immunol 171 (2003)1343-1351).

25 HLA-G is predominantly expressed on cytotrophoblasts in the placenta. Several tumors (including pancreatic, breast, skin, colorectal, gastric & ovarian) express HLA-G (Lin, A. et al., Mol Med. 21 (2015) 782–791; Amiot, L., et al., Cell Mol Life Sci. 68 (2011) 417–431). The expression has also been reported to be associated with pathological conditions like inflammatory diseases, GvHD and cancer. Expression of HLA-G has been reported to be associated with poor prognosis in cancer. Tumor

30 cells escape host immune surveillance by inducing immune tolerance/suppression via HLA-G expression.

- 2 -

Overview polymorphisms HLA family		
• HLA-A:	2579 seqs	} <u>classical</u> class I MHC
• HLA-B:	3283 seqs	
• HLA-C:	2133 seqs	
• HLA-E:	15 seqs	} <u>non-classical</u> class I MHC
• HLA-F:	22 seqs	
• HLA-G:	50 seqs	

HLA-G shares high homology (>98%) with other MHC I molecules, therefore truly HLA-G specific antibodies with no crossreactivity to other MHC I molecules are difficult to generate.

5 Certain antibodies which interact in different ways with HLA-G were described previously: Tissue Antigens, 55 (2000) 510-518 relates to monoclonal antibodies e.g. 87G, and MEM-G/9; Neoplasma 50 (2003) 331-338 relates to certain monoclonal antibodies recognizing both, intact HLA-G oligomeric complex (e.g. 87G and MEM-G9) as well as HLA-G free heavy chain (e.g. 4H84, MEM-G/1 and MEM-G/2); Hum
10 Immunol. 64 (2003) 315-326 relates to several antibodies tested on HLA-G expressing JEG3 tumor cells (e.g. MEM-G/09 and -G/13 which react exclusively with native HLA-G1 molecules. MEM-G/01 recognizes (similar to the 4H84 mAb) the denatured HLA-G heavy chain of all isoforms, whereas MEM-G/04 recognizes selectively denatured HLA-G1, -G2, and -G5 isoforms; Wiendl et al Brain 2003 176-
15 85 relates to different monoclonal HLA-G antibodies as e.g. 87G, 4H84, MEM-G/9.

The above publications report antibodies, which bind to human HLA-G or the human HLA-G/ β 2M MHC complex. However, due to the high polymorphism and high homology of the HLA family most of the antibodies lack either truly specific HLA-G binding properties and often also bind or crossreact with other HLA family
20 members (either as MHC complex with β 2M or in its β 2M-free form) or they simply do not inhibit binding of HLA-G β 2M MHC complex to its receptors ILT2 and/or ILT4 (and are regarded as non-antagonistic antibodies).

Hence there is the need to generate and/or select further improved, truly HLA-G specific antibodies with receptor inhibition properties.

25

Summary of the Invention

In one aspect, the invention provides an antibody that bind to human HLA-G (and that inhibits ILT2 binding to HLAG on JEG-3 cells (ATCC HTB36) and restores HLA-G specific suppressed TNF alpha release by monocytes co-cultured with JEG-3 cells.

One embodiment of the invention is an isolated antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

A) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:3; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6; or

B) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:10, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:11; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:13 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14; or

C) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:18, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:19; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:20; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:21 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:22; or

D) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:26, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:27; and (b) a VL domain comprising (i) HVR-L1 comprising the

- 4 -

amino acid sequence of SEQ ID NO:28; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:29 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.

5 One embodiment of the invention is an isolated antibody that binds to human HLA-G(in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody

A)

i) comprises a VH sequence of SEQ ID NO:7 and a VL sequence of SEQ ID NO:8;

10 ii) or humanized variant of the VH and VL of the antibody under i);or

B)

i) comprises a VH sequence of SEQ ID NO:15 and a VL sequence of SEQ ID NO:16;

ii) or humanized variant of the VH and VL of the antibody under i);or

15 C)

i) comprises a VH sequence of SEQ ID NO:23 and a VL sequence of SEQ ID NO:24;

ii) or humanized variant of the VH and VL of the antibody under i); or

D)

20 i) comprises a VH sequence of SEQ ID NO:31 and a VL sequence of SEQ ID NO:32;

ii) or humanized variant of the VH and VL of the antibody under i).

In one embodiment the anti-HLA-G antibody described herein

25 a) does not crossreact with a modified human HLA-G β 2M MHC I complex comprising SEQ ID NO:44; and/ or

- 5 -

- b) does not crossreact with human HLA-A2 β 2M MHC I complex comprising SEQ ID NO:39 and SEQ ID NO: 37; and/ or
- c) does not crossreact with a mouse H2Kd β 2M MHC I complex comprising SEQ ID NO:45; and/ or
- 5 d) does not crossreact with rat RT1A β 2M MHC I complex comprising SEQ ID NO:47; and/ or
- e) inhibits ILT2 binding to monomeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43); and/or
- 10 f) inhibits ILT2 binding to trimeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43), by more than 50% (in one embodiment by more than 60 %) (when compared to the binding without antibody) (see Example 4b); and/or
- 15 g) inhibits ILT2 binding to monomeric and/or dimeric and/or trimeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43), by more than 50% (in on embodiment by more than 80 %) (when compared to the binding without antibody) (see Example 4b); and/ or
- 20 h) inhibits ILT2 binding to (HLA-G on) JEG3 cells (ATCC No. HTB36) (by more than 50 % (in one embodiment by more than 80%)) (when compared to the binding without antibody) (see Example 6); and/or
- i) binds to (HLA-G on) JEG3 cells (ATCC No. HTB36) (see Example 5), and inhibits ILT2 binding to (HLA-G on) JEG3 cells (ATCC No. HTB36) (by more than 50 % (in one embodiment by more than 80%)) (when compared to the binding without antibody) (see Example 6); and/or
- 25 j) inhibits CD8a binding to HLAG by more than 80% (when compared to the binding without antibody) (see e.g Example 4c).

In one embodiment the anti-HLA-G antibody is of IgG1 isotype.

In one embodiment the anti-HLA-G antibody is of IgG1 isotype with mutations L234A, L235A and P329G (numbering according to the EU index of Kabat).

- 6 -

In one preferred embodiment the anti-HLA-G antibody inhibits ILT2 binding to monomeric HLA-G β 2M MHC I complex.

In one embodiment the anti-HLA-G antibody according to the invention is a monoclonal antibody.

5 In one embodiment the anti-HLA-G antibody according to the invention is a human, humanized, or chimeric antibody.

In one embodiment the anti-HLA-G antibody according to the invention which is an antibody fragment that binds to HLA-G.

10 In one embodiment the anti-HLA-G antibody according to the invention which is Fab fragment.

The invention provides an isolated nucleic acid encoding the antibody according to any one of the preceding claims.

The invention provides a host cell comprising such nucleic acid.

15 The invention provides a method of producing an antibody comprising culturing the host cell so that the antibody is produced.

The invention provides such method of producing an antibody, further comprising recovering the antibody from the host cell.

The invention provides a pharmaceutical formulation comprising the antibody described herein and a pharmaceutically acceptable carrier.

20 The invention provides the antibody described herein for use as a medicament.

The invention provides the antibody described herein for use in treating cancer.

The invention provides the use of the antibody described herein in the manufacture of a medicament. In one embodiment the medicament is for treatment of cancer.

25 The invention provides a method of treating an individual having cancer comprising administering to the individual an effective amount of the antibody described herein.

The present invention uses tailor-made chimeric antigens and/or stringent screening assays to identify HLA-G specific antibodies among numerous candidates (avoiding cross-reactivity to other MHC class I complex molecules and at the same time

- 7 -

selecting HLA-G receptor (such as ILT2) blocking antibodies) which show HLA-G-specific induction (restoration) of TNF alpha in co-cultures of HLA-G expressin JEG-3 cells and monocytes. With these screening methods described herein new anti-HLA-G antibodies could be selected. These antibodies show highly valuable properties like strong inhibition of ILT2 binding to HLA-G expressed on JEG3 cells or inhibition of ILT2 binding to monomeric and/or dimeric and/or trimeric HLA-G β 2M MHC I complex.

The invention provides antibodies that specifically binds to human HLA-G, inhibit ILT2 binding to HLAG, and restore a HLA-G specific suppressed immune response, restoration of Lipopolysaccharide (LPS) -induced TNFalpha production/secretion by monocytes in co-culture with HLA-G-expressing cells (as e.g. JEG-3 cells). The restoration of a truly HLA-G specific immune suppression of monocytes by HLA-G expressing cells like JEG-3 cells can be evaluated in comparison to JEG-3 cells with a HLA-G knock-out.

Thus the antibodies of the invention restore a HLAG specific release of TNF alpha in Lipopolysaccharide (LPS) stimulated co-cultures of HLA-G expressin JEG-3 cells and monocytes compared to untreated co-cultred JEG-3 cells (untreated cells are taken 0% negative reference; monocyte only cultures are taken as 100% positive reference, in which TNF alpha section is not suppressed by any HLA-G /IL-T2 specific effects((see Example 7).

In addition, the antibodies are highly specific and to not show cross reactivity with HLA-A MHC I complexes or MHC I complexes from mouse or rat origin.

Description of the Figures

Figure 1: Different isoforms of HLA-G

Figure 2: **Fig. 2A:** Schematic representation of HLA-G with molecule in association with β 2M

Fig. 2B: Structure of HLA-G molecule in association with certain receptors : HLA-G structure in complex with given receptors such as ILT4 and KIR2DL1. ILT4 structure (PDB code: 2DYP). The KIR2DL1 structure is taken from PDB code 1IM9 (KIR2DL1: HLA-Cw4 complex structure) and was positioned on HLA-G by superposition of the HLA-Cw4 and HLA-G structures. Receptors are shown in a ribbon representation, HLA-G is shown

in a molecular surface representation. HLA-G residues that are unique or conserved in other HLA paralogs are colored in white and gray, respectively. Unique surface residues were replaced by a HLA consensus sequence in the chimeric counter antigen.

5 **Figure 3:** HLA-G antibodies which inhibit (or stimulate) HLA-G interaction/binding with ILT2 and ILT4 as well as CD8:

Figure 3A: ILT2 inhibition

Figure 3B: ILT4 inhibition

Figure 3C: CD8 inhibition

10 **Figure 4:** Flow cytometric analysis of cell surface expression of HLA-G using HLA-G antibodies on JEG3 (cells naturally expressing HLA-G), SKOV-3 cells (wild-type (wt) versus HLAG transfected cells (HLAG+)) , and PA-TU-8902 cells (wild-type (wt) versus HLAG transfected cells (HLAG+)):

15 **Fig. 4A:** HLA-G-0031 (#0031); **Fig. 4B:** HLA-G-0039 (#0039); **Fig. 4C:** HLA-G-0041 (#0041); **Fig. 4D:** HLA-G-0090 (#0090)

Figure 5: **Fig. 5A:** Anti-HLA-G antibodies (0031, 0039, 0041 and 0090) block/modulate interaction of human ILT2 Fc chimera with HLA-G expressed on JEG3 cells:

20 The staining of cell surface HLA-G with the novel anti-HLA-G antibodies was assessed by using an anti-rat IgG secondary antibody conjugated to Alexa488 (*upper row*). Shown in the FACS histograms are cells stained with secondary antibody alone (grey dotted lines) and cell stained with anti-HLA-G antibodies (black solid lines). In *the lower row* human ILT2-Fc bound to HLA-G on JEG3 cells is depicted (black dotted line) in comparison to cells stained with secondary antibody alone (grey dotted line). The impact of pre-incubating JEG3 cells with HLA-G antibodies on ILT2 Fc chimera binding can be seen (black solid line): HLA-G-0031 and HLA-G-0090 showed nearly complete inhibition of binding of ILT2-Fc chimera to JEG3 cells. Interestingly, the two antibodies 0039 and 0041 even increase ILT2:fc binding to the cells.

25

30

Fig. 5B: Impact of commercial/reference anti-HLA-G antibodies on ILT2 Fc chimera binding to HLA-G on JEG3 cells:.

The staining of cell surface HLA-G with commercial/reference anti-HLA-G antibodies was assessed by using a species-specific secondary antibody conjugated to Alexa488 (*upper row*). Shown in the FACS histograms are cells stained with secondary antibody alone (grey dotted lines) and cell stained with anti-HLA-G antibodies (black solid lines). In *the lower row* human ILT2 Fc chimera bound to HLA-G on JEG3 cells is depicted (black dotted line) in comparison to cells stained with secondary antibody alone (grey dotted line). The impact of pre-incubating JEG3 cells with reference antibodies on ILT2 Fc chimera binding can be seen (black solid line). None of the tested reference antibodies could block the interaction of ILT2 Fc chimera with cell surface HLA-G on JEG3 cells.

Figure 6: The impact of the blockade of HLA-G with inhibitory anti-HLA-G antibodies on the restoration of TNF α production assessed on different donors.

Figure 6A: Anti-HLAG antibodies HLA-G-0031 (#0031), HLA-G-0039 (#0039), and HLA-G-0041 (#0041) evaluated on a representative monocyte donor.

Figure 6B: Anti-HLAG antibody HLA-G-0090 (#0090) evaluated on a different monocyte donor.

Figure 6C: Western blot analysis of HLAG expression in wt JEG-3 cells and knock down variants.

Detailed Description of the Invention

When used herein, the term “HLA-G”, “human HLA-G”, refers to the HLA-G human major histocompatibility complex, class I, G, also known as human leukocyte antigen G (HLA-G) (exemplary SEQ ID NO: 35). Typically, HLA-G forms a MHC class I complex together with β 2 microglobulin (B2M or β 2m). In one embodiment HLA-G refers to the MHC class I complex of HLA-G and β 2 microglobulin.

As used herein, an antibody "binding to human HLA-G", "specifically binding to human HLA-G", "that binds to human HLA-G" or "anti-HLA-G antibody" refers to an antibody specifically binding to the human HLA-G antigen or its extracellular

- 10 -

domain (ECD) with a binding affinity of a K_D -value of 5.0×10^{-8} mol/l or lower, in one embodiment of a K_D -value of 1.0×10^{-9} mol/l or lower, in one embodiment of a K_D -value of 5.0×10^{-8} mol/l to 1.0×10^{-13} mol/l. In one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43).

5 The binding affinity is determined with a standard binding assay, such as surface plasmon resonance technique (BIAcore®, GE-Healthcare Uppsala, Sweden) e.g. using constructs comprising HLA-G extracellular domain (e.g. in its natural occurring 3 dimensional structure). In one embodiment binding affinity is determined with a standard binding assay using exemplary soluble HLA-G
10 comprising MHC class I complex comprising SEQ ID NO: 43.

HLA-G has the regular MHC I fold and consists of two chains: Chain 1 consists of three domains: alpha 1, alpha 2 and alpha 3. The alpha 1 and alpha 2 domains form a peptide binding groove flanked by two alpha helices. Small peptides (approximately 9mers) can bind to this groove akin to other MHCI proteins. Chain
15 2 is beta 2 microglobulin which is shared with various other MHCI proteins.

HLA-G can form functionally active complex oligomeric structures (Kuroki, K et al. Eur J Immunol. 37 (2007) 1727–1729). Disulfide-linked dimers are formed between Cys 42 of two HLA-G molecules. (Shiroishi M et al., J Biol Chem 281 (2006) 10439-10447. Trimers and Tetrameric complexes have also been described e.g. in Kuroki, K et al. Eur J Immunol. 37 (2007) 1727–1729, Allan D.S., et al. J Immunol Methods. 20 268 (2002) 43-50 and T Gonen-Gross et al., J Immunol 171 (2003)1343-1351). HLA-G has several free cysteine residues, unlike most of the other MHC class I molecules. Boyson et al., Proc Nat Acad Sci USA, 99: 16180 (2002) reported that the recombinant soluble form of HLA-G5 could form a disulfide-linked dimer with
25 the intermolecular Cys42-Cys42 disulfide bond. In addition, the membrane-bound form of HLA-G1 can also form a disulfide-linked dimer on the cell surface of the Jeg3 cell line, which endogenously expresses HLA-G. Disulfide-linked dimer forms of HLA-G1 and HLA-G5 have been found on the cell surface of trophoblast cells as well (Apps, R., Tissue Antigens, 68:359 (2006)).

30 HLA-G is predominantly expressed on cytotrophoblasts in the placenta. Several tumors (including pancreatic, breast, skin, colorectal, gastric & ovarian) express HLA-G (Lin, A. et al., Mol Med. 21 (2015) 782–791; Amiot, L., et al., Cell Mol Life Sci. 68 (2011) 417–431). The expression has also been reported to be associated with pathological conditions like inflammatory diseases, GvHD and cancer. Expression

of HLA-G has been reported to be associated with poor prognosis in cancer. Tumor cells escape host immune surveillance by inducing immune tolerance/suppression via HLA-G expression.

5 For HLA-G there exist 7 isoforms, 3 secreted and 4 membrane bound forms (as schematically shown in Fig.1). The most important functional isoforms of HLA-G include b2-microglobulin-associated HLA-G1 and HLA-G5. However, the tolerogenic immunological effect of these isoforms is different and is dependent on the form (monomer, dimer) of ligands and the affinity of the ligand-receptor interaction.

10 HLA-G protein can be produced using standard molecular biology techniques. The nucleic acid sequence for HLA-G isoforms is known in the art. See for example GENBANK Accession No. AY359818.

The HLA-G isomeric forms promote signal transduction through ILTs, in particular ILT2, ILT4, or a combination thereof.

15 ILTs: ILTs represent Ig types of activating and inhibitory receptors that are involved in regulation of immune cell activation and control the function of immune cells (Borges, L., et al., *Curr Top Microbial Immunol*, 244:123-136 (1999)). ILTs are categorized into three groups: (i) inhibitory, those containing a cytoplasmic immunoreceptor tyrosine-based inhibitory motif (ITIM) and transducing an
20 inhibitory signal (ILT2, ILT3, ILT4, ILT5, and LIR8); (ii) activating, those containing a short cytoplasmic tail and a charged amino acid residue in the transmembrane domain (ILT1, ILT7, ILT8, and LIR6alpha) and delivering an activating signal through the cytoplasmic immunoreceptor tyrosine-based activating motif (ITAM) of the associated common gamma chain of Fc receptor; and (iii) the
25 soluble molecule ILT6 lacking the transmembrane domain. A number of recent studies have highlighted immunoregulatory roles for ILTs on the surface of antigen presenting cells (APC). ILT2, ILT3, and ILT4 receptors, the most characterized immune inhibitory receptors, are expressed predominantly on myeloid and plasmacytoid DC. ILT3 and ILT4 are upregulated by exposing immature DC to
30 known immunosuppressive factors, including IL-10, vitamin D3, or suppressor CD8 T cells (Chang, C. C., et al., *Nat Immunol*, 3:237-243 (2002)). The expression of ILTs on DC is tightly controlled by inflammatory stimuli, cytokines, and growth factors, and is down-regulated following DC activation (Ju, X. S., et al., *Gene*, 331:159-164 (2004)). The expression of ILT2 and ILT4 receptors is highly regulated

by histone acetylation, which contributes to strictly controlled gene expression exclusively in the myeloid lineage of cells (Nakajima, H., *J Immunol*, 171:6611-6620 (2003)).

5 Engagement of the inhibitory receptors ILT2 and ILT4 alters the cytokine and chemokine secretion/release profile of monocytes and can inhibit Fc receptor signaling (Colonna, M., et al. *J Leukoc Biol*, 66:375-381 (1999)). The role and function of ILT3 on DC have been precisely described by the Suci-Foca group (Suci-Foca, N., *Int Immunopharmacol*, 5:7-11 (2005)). Although the ligand for ILT3 is unknown, ILT4 is known to bind to the third domain of HLA class I
10 molecules (HLA-A, HLA-B, HLA-C, and HLA-G), competing with CD8 for MHC class I binding (Shiroishi, M., *Proc Natl Acad Sci USA*, 100:8856-8861 (2003)). The preferential ligand for several inhibitory ILT receptors is HLA-G. HLA-G plays a potential role in maternal-fetal tolerance and in the mechanisms of escape of tumor cells from immune recognition and destruction (Hunt, J. S., et al., *Faseb J*, 19:681-
15 693 (2005)). It is most likely that regulation of DC function by HLA-G-ILT interactions is an important pathway in the biology of DC. It has been determined that human monocyte-derived DC that highly express ILT2 and ILT4 receptors, when treated with HLA-G and stimulated with allogeneic T cells, still maintain a stable tolerogenic-like phenotype (CD80^{low}, CD86^{low}, HLA-DR^{low}) with the potential to induce T cell anergy (Ristich, V., et al., *Eur J Immunol*, 35:1133-1142
20 (2005)). Moreover, the HLA-G interaction with DC that highly express ILT2 and ILT4 receptors resulted in down-regulation of several genes involved in the MHC class II presentation pathway. A lysosomal thiol reductase, IFN-gamma inducible lysosomal thiol reductase (GILT), abundantly expressed by professional APC, was greatly reduced in HLA-G-modified DC. The repertoire of primed CD4⁺ T cells can be influenced by DC expression of GILT, as in vivo T cell responses to select antigens were reduced in animals lacking GILT after targeted gene disruption (Marie, M., et al., *Science*, 294:1361-1365 (2001)). The HLA-G/ILT interaction on DC interferes with the assembly and transport of MHC class II molecules to the cell
30 surface, which might result in less efficient presentation or expression of structurally abnormal MHC class II molecules. It was determined that HLA-G markedly decreased the transcription of invariant chain (CD74), HLA-DMA, and HLA-DMB genes on human monocyte-derived DC highly expressing ILT inhibitory receptors (Ristich, V., et al; *Eur J Immunol* 35:1133-1142 (2005)).

35 Another receptor of HLA-G is KIR2DL4 because KIR2DL4 binds to cells expressing HLA-G (US2003232051; Cantoni, C. et al. *Eur J Immunol* 28 (1998)

1980; Rajagopalan, S. and E. O. Long. [published erratum appears in J Exp Med 191 (2000) 2027] J Exp Med 189 (1999) 1093; Ponte, M. et al. PNAS USA 96 (1999) 5674). KIR2DL4 (also referred to as 2DL4) is a KIR family member (also designated CD158d) that shares structural features with both activating and inhibitory receptors (Selvakumar, A. et al. Tissue Antigens 48 (1996) 285). 2DL4 has a cytoplasmic ITIM, suggesting inhibitory function, and a positively charged amino acid in the transmembrane region, a feature typical of activating KIR. Unlike other clonally distributed KIRs, 2DL4 is transcribed by all NK cells (Valiante, N. M. et al. Immunity 7 (1997) 739; Cantoni, C. et al. Eur J Immunol 28 (1998) 1980; Rajagopalan, S. and E. O. Long. [published erratum appears in J Exp Med 191 (2000) 2027] J Exp Med 189 (1999) 1093).

HLA-G has also been shown to interact with CD8 (Sanders et al, J. Exp. Med., 1991) on cytotoxic T cells and induce CD95 mediated apoptosis in activated CD8 positive cytotoxic T cells (Fournel et al, J. Immun., 2000). This mechanism of elimination of cytotoxic T cells has been reported to one of the mechanisms of immune escape and induction of tolerance in pregnancy, inflammatory diseases and cancer (Amodio G. et al, Tissue Antigens, 2014).

As used herein an anti-HLA-G antibody that “does not crossreact with “or that “does not specifically bind to“ a modified human HLA-G β 2M MHC I complex comprising SEQ ID NO:44; a mouse H2Kd β 2M MHC I complex comprising SEQ ID NO:45 rat RT1A β 2M MHC I complex comprising SEQ ID NO:47, human HLA-A2 β 2M MHC I complex comprising SEQ ID NO:39 and SEQ ID NO: 37 refers to an anti-HLA-G antibody that does substantially not bind to any of these counterantigens. In one embodiment an anti-HLA-G antibody that “does not crossreact with “ or that “does not specifically bind to“ a modified human HLA-G β 2M MHC I complex comprising SEQ ID NO:44; a mouse H2Kd β 2M MHC I complex comprising SEQ ID NO:45, a rat RT1A β 2M MHC I complex comprising SEQ ID NO:47, and/or a human HLA-A2 β 2M MHC I complex comprising SEQ ID NO:39 and SEQ ID NO: 37 refers to an anti-HLA-G antibody that shows only unspecific binding with a binding affinity of a K_D -value of 5.0×10^{-6} mol/l or higher (until no more binding affinity is detectable). The binding affinity is determined with a standard binding assay, such as surface plasmon resonance technique (BIAcore®, GE-Healthcare Uppsala, Sweden) with the respective antigen: a modified human HLA-G β 2M MHC I complex comprising SEQ ID NO:44; a mouse H2Kd β 2M MHC I complex comprising SEQ ID NO:45 rat RT1A β 2M MHC I complex comprising SEQ ID NO:47, and/or a human HLA-A2 β 2M MHC I complex comprising SEQ ID NO:39

- 14 -

and SEQ ID NO: 37 The assay setup as well as the construction/preparation of the antigens is described in the Examples.

5 The term “inhibits ILT2 binding to HLAG on JEG-3 cells (ATCC HTB36)” refers to the inhibition of binding interaction of recombinant ILT2 in an assay as described e.g. in Example 6.

10 The terms “restoration of HLA-G specific suppressed immune response” or to “restore HLA-G specific suppressed immune response” refers to a restoration of Lipopolysaccharide (LPS)-induced TNFalpha production by monocytes in co-culture with HLA-G-expressing cells in particular JEG-3 cells. Thus the antibodies of the invention restore a HLAG specific release of TNF alpha in Lipopolysaccharide (LPS) stimulated co-cultures of HLA-G expressing JEG-3 cells (ATCC HTB36) and monocytes compared to untreated co-cultured JEG-3 cells (untreated co-cultures are taken 0% negative reference; monocyte only cultures are taken as 100% positive reference, in which TNF alpha secretion is not suppressed by any HLA-G /IL-2 specific effects((see Example 7). In this context “HLA-G specific suppressed immune response” refers to a immune suppression of monocytes due to the HLA-G expression on JEG-3 cells. In contrast, the anti-HLA-G antibodies of the present invention are not able to restore the immune response by monocytes co-cultured with JEG3 cell with an HLA-G knock out. As other commercial anti-HLA-G s are able to induce TNF alpha by monocytes co-cultured with JEG3 cell with an HLA-G knock out, these antibodies , there is a non-HLA-G specific TNF alpha release by these antibodies.

25 An “acceptor human framework” for the purposes herein is a framework comprising the amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework, as defined below. An acceptor human framework “derived from” a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes are 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to the VL human immunoglobulin framework sequence or human consensus framework sequence. A preferred VH acceptor human framework for a humanized variant of the obtained antibody HLAG-0031 is HUMAN_IGHV1-3. A preferred VL acceptor human framework for a humanized variant of the

30

35

obtained antibody HLAG-0031 are HUMAN_IGKV1-17 (V-domain, with one additional back-mutation at position R46F, Kabat numbering).

5 The term "antibody" herein is used in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, multispecific antibodies (e.g., bispecific antibodies), and antibody fragments so long as they exhibit the desired antigen-binding activity.

10 An "antibody fragment" refers to a molecule other than an intact antibody that comprises a portion of an intact antibody that binds the antigen to which the intact antibody binds. Examples of antibody fragments include but are not limited to Fv, Fab, Fab', Fab'-SH, F(ab')₂; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments.

15 An "antibody that binds to the same epitope" as a reference antibody refers to an antibody that blocks binding of the reference antibody to its antigen in a competition assay by 50% or more, and conversely, the reference antibody blocks binding of the antibody to its antigen in a competition assay by 50% or more. An exemplary competition assay is provided herein.

The term "chimeric" antibody refers to an antibody in which a portion of the heavy and/or light chain is derived from a particular source or species, while the remainder of the heavy and/or light chain is derived from a different source or species.

20 The "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes), e.g., IgG₁, IgG₂, IgG₃, IgG₄, IgA₁, and IgA₂. The heavy chain constant domains that correspond to the different classes of immunoglobulins are called α , δ , ϵ , γ , and μ , respectively.

30 The term "cytotoxic agent" as used herein refers to a substance that inhibits or prevents a cellular function and/or causes cell death or destruction. Cytotoxic agents include, but are not limited to, radioactive isotopes (e.g., At211, I131, I125, Y90, Re186, Re188, Sm153, Bi212, P32, Pb212 and radioactive isotopes of Lu); chemotherapeutic agents or drugs (e.g., methotrexate, adriamycin, vinca alkaloids (vincristine, vinblastine, etoposide), doxorubicin, melphalan, mitomycin C, chlorambucil, daunorubicin or other intercalating agents); growth inhibitory agents; enzymes and fragments thereof such as nucleolytic enzymes; antibiotics; toxins such

- 16 -

as small molecule toxins or enzymatically active toxins of bacterial, fungal, plant or animal origin, including fragments and/or variants thereof; and the various antitumor or anticancer agents disclosed below.

5 An "effective amount" of an agent, e.g., a pharmaceutical formulation, refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired therapeutic or prophylactic result.

The term "Fc region" herein is used to define a C-terminal region of an immunoglobulin heavy chain that contains at least a portion of the constant region. The term includes native sequence Fc regions and variant Fc regions. In one
10 embodiment, a human IgG heavy chain Fc region extends from Cys226, or from Pro230, to the carboxyl-terminus of the heavy chain. However, the C-terminal lysine (Lys447), or the C-terminal glycine (Gly446) and the C-terminal lysine (Lys447), of the Fc region may or may not be present. In one embodiment the anti-HLA-G antibody as described herein is of IgG1 isotype and comprises a constant heavy chain
15 domain of SEQ ID NO: 53 or of SEQ ID NO: 54. In one embodiment it comprises additionally the the C-terminal glycine (Gly446). In one embodiment it comprises additionally the the C-terminal glycine (Gly446) and the C-terminal lysine (Lys447). In one embodiment the anti- HLA-G antibody as described herein is of IgG4 isotype and comprises and constant heavy chain domain of SEQ ID NO: 55. In one
20 embodiment it comprises additionally the the C-terminal glycine (Gly446). In one embodiment it comprises additionally the the C-terminal glycine (Gly446) and theC-terminal lysine (Lys447). Unless otherwise specified herein, numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also called the EU index, as described in Kabat, E.A. et al., Sequences of
25 Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991), NIH Publication 91-3242.

"Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Accordingly, the HVR and FR sequences
30 generally appear in the following sequence in VH (or VL): FR1-H1(L1)-FR2-H2(L2)-FR3-H3(L3)-FR4.

The terms "full length antibody", "intact antibody", and "whole antibody" are used herein interchangeably to refer to an antibody having a structure substantially similar

to a native antibody structure or having heavy chains that contain an Fc region as defined herein.

5 The terms "host cell," "host cell line," and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acid has been introduced, including the progeny of such cells. Host cells include "transformants" and "transformed cells," which include the primary transformed cell and progeny derived therefrom without regard to the number of passages. Progeny may not be completely identical in nucleic acid content to a parent cell, but may contain mutations. Mutant progeny that have the same function or biological activity as
10 screened or selected for in the originally transformed cell are included herein.

A "human antibody" is one which possesses an amino acid sequence which corresponds to that of an antibody produced by a human or a human cell or derived from a non-human source that utilizes human antibody repertoires or other human antibody-encoding sequences. This definition of a human antibody specifically
15 excludes a humanized antibody comprising non-human antigen-binding residues.

A "human consensus framework" is a framework which represents the most commonly occurring amino acid residues in a selection of human immunoglobulin VL or VH framework sequences. Generally, the selection of human immunoglobulin VL or VH sequences is from a subgroup of variable domain sequences. Generally,
20 the subgroup of sequences is a subgroup as in Kabat, E.A. et al., Sequences of Proteins of Immunological Interest, 5th ed., Bethesda MD (1991), NIH Publication 91-3242, Vols. 1-3. In one embodiment, for the VL, the subgroup is subgroup kappa I as in Kabat et al., *supra*. In one embodiment, for the VH, the subgroup is subgroup III as in Kabat et al., *supra*.

25 A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one, and typically two, variable domains, in which all or substantially all of the HVRs (e.g., CDRs) correspond to those of a non-human antibody, and all or substantially
30 all of the FRs correspond to those of a human antibody. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, e.g., a non-human antibody, refers to an antibody that has undergone humanization.

The term “hypervariable region” or “HVR” as used herein refers to each of the regions of an antibody variable domain which are hypervariable in sequence (“complementarity determining regions” or “CDRs”) and/or form structurally defined loops (“hypervariable loops”) and/or contain the antigen-contacting residues (“antigen contacts”). Generally, antibodies comprise six HVRs: three in the VH (H1, H2, H3), and three in the VL (L1, L2, L3). Exemplary HVRs herein include:

- 5 (a) hypervariable loops occurring at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, *J. Mol. Biol.* 196:901-917 (1987));
- 10 (b) CDRs occurring at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35b (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991));
- 15 (c) antigen contacts occurring at amino acid residues 27c-36 (L1), 46-55 (L2), 89-96 (L3), 30-35b (H1), 47-58 (H2), and 93-101 (H3) (MacCallum et al. *J. Mol. Biol.* 262: 732-745 (1996)); and
- (d) combinations of (a), (b), and/or (c), including HVR amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35 (H1), 50-63 (H2), and 95-102 (H3).

Unless otherwise indicated, HVR residues and other residues in the variable domain (e.g., FR residues) are numbered herein according to Kabat et al., *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991).

An “immunoconjugate” is an antibody conjugated to one or more heterologous molecule(s), including but not limited to a cytotoxic agent.

25 An “individual” or “subject” is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cows, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). In certain embodiments, the individual or subject is a human.

30 An “isolated” antibody is one which has been separated from a component of its natural environment. In some embodiments, an antibody is purified to greater than 95% or 99% purity as determined by, for example, electrophoretic (e.g., SDS-PAGE, isoelectric focusing (IEF), capillary electrophoresis) or chromatographic (e.g., ion

exchange or reverse phase HPLC). For review of methods for assessment of antibody purity see, e.g., Flatman, S. et al., J. Chromatogr. B 848 (2007) 79-87.

5 An "isolated" nucleic acid refers to a nucleic acid molecule that has been separated from a component of its natural environment. An isolated nucleic acid includes a nucleic acid molecule contained in cells that ordinarily contain the nucleic acid molecule, but the nucleic acid molecule is present extrachromosomally or at a chromosomal location that is different from its natural chromosomal location.

10 "Isolated nucleic acid encoding an anti-HLA-G antibody" refers to one or more nucleic acid molecules encoding antibody heavy and light chains (or fragments thereof), including such nucleic acid molecule(s) in a single vector or separate vectors, and such nucleic acid molecule(s) present at one or more locations in a host cell.

15 The term "monoclonal antibody" as used herein refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical and/or bind the same epitope, except for possible variant antibodies, e.g., containing naturally occurring mutations or arising during production of a monoclonal antibody preparation, such variants generally being present in minor amounts. In contrast to polyclonal antibody preparations, which typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody of a monoclonal antibody preparation is directed against a single determinant on an antigen. Thus, the modifier "monoclonal" indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by a variety of techniques, including but not limited to the hybridoma method, recombinant DNA methods, phage-display methods, and methods utilizing transgenic animals containing all or part of the human immunoglobulin loci, such methods and other exemplary methods for making monoclonal antibodies being described herein.

20

25

30

"Native antibodies" refer to naturally occurring immunoglobulin molecules with varying structures. For example, native IgG antibodies are heterotetrameric glycoproteins of about 150,000 daltons, composed of two identical light chains and two identical heavy chains that are disulfide-bonded. From N- to C-terminus, each

- 20 -

heavy chain has a variable region (VH), also called a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3). Similarly, from N- to C-terminus, each light chain has a variable region (VL), also called a variable light domain or a light chain variable domain, followed by a constant light (CL) domain. The light chain of an antibody may be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of its constant domain.

The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and/or warnings concerning the use of such therapeutic products.

"Percent (%) amino acid sequence identity" with respect to a reference polypeptide sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical with the amino acid residues in the reference polypeptide sequence, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent sequence identity, and not considering any conservative substitutions as part of the sequence identity. Alignment for purposes of determining percent amino acid sequence identity can be achieved in various ways that are within the skill in the art, for instance, using publicly available computer software such as BLAST, BLAST-2, ALIGN or Megalign (DNASTAR) software. Those skilled in the art can determine appropriate parameters for aligning sequences, including any algorithms needed to achieve maximal alignment over the full length of the sequences being compared. For purposes herein, however, % amino acid sequence identity values are generated using the sequence comparison computer program ALIGN-2. The ALIGN-2 sequence comparison computer program was authored by Genentech, Inc., and the source code has been filed with user documentation in the U.S. Copyright Office, Washington D.C., 20559, where it is registered under U.S. Copyright Registration No. TXU510087. The ALIGN-2 program is publicly available from Genentech, Inc., South San Francisco, California, or may be compiled from the source code. The ALIGN-2 program should be compiled for use on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and do not vary.

In situations where ALIGN-2 is employed for amino acid sequence comparisons, the % amino acid sequence identity of a given amino acid sequence A to, with, or against a given amino acid sequence B (which can alternatively be phrased as a given

- 21 -

amino acid sequence A that has or comprises a certain % amino acid sequence identity to, with, or against a given amino acid sequence B) is calculated as follows:

$$100 \text{ times the fraction } X/Y$$

5 where X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and where Y is the total number of amino acid residues in B. It will be appreciated that where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values used herein are obtained as described in the immediately preceding paragraph using the ALIGN-2 computer program.

10 The term "pharmaceutical formulation" refers to a preparation which is in such form as to permit the biological activity of an active ingredient contained therein to be effective, and which contains no additional components which are unacceptably toxic to a subject to which the formulation would be administered.

15 A "pharmaceutically acceptable carrier" refers to an ingredient in a pharmaceutical formulation, other than an active ingredient, which is nontoxic to a subject. A pharmaceutically acceptable carrier includes, but is not limited to, a buffer, excipient, stabilizer, or preservative.

20 As used herein, "treatment" (and grammatical variations thereof such as "treat" or "treating") refers to clinical intervention in an attempt to alter the natural course of the individual being treated, and can be performed either for prophylaxis or during the course of clinical pathology. Desirable effects of treatment include, but are not limited to, preventing occurrence or recurrence of disease, alleviation of symptoms, 25 diminishment of any direct or indirect pathological consequences of the disease, preventing metastasis, decreasing the rate of disease progression, amelioration or palliation of the disease state, and remission or improved prognosis. In some embodiments, antibodies of the invention are used to delay development of a disease or to slow the progression of a disease.

30 The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in binding the antibody to antigen. The variable domains of the heavy chain and light chain (VH and VL, respectively) of a native antibody generally have similar structures, with each domain comprising four

- 22 -

conserved framework regions (FRs) and three hypervariable regions (HVRs). (See, e.g., Kindt, T.J. et al. Kuby Immunology, 6th ed., W.H. Freeman and Co., N.Y. (2007), page 91) A single VH or VL domain may be sufficient to confer antigen-binding specificity. Furthermore, antibodies that bind a particular antigen may be isolated using a VH or VL domain from an antibody that binds the antigen to screen a library of complementary VL or VH domains, respectively. See e.g., Portolano, S. et al., J. Immunol. 150 (1993) 880-887; Clackson, T. et al., Nature 352 (1991) 624-628).

The term "vector," as used herein, refers to a nucleic acid molecule capable of propagating another nucleic acid to which it is linked. The term includes the vector as a self-replicating nucleic acid structure as well as the vector incorporated into the genome of a host cell into which it has been introduced. Certain vectors are capable of directing the expression of nucleic acids to which they are operatively linked. Such vectors are referred to herein as "expression vectors".

I. COMPOSITIONS AND METHODS

In one aspect, the invention is based, in part, on the finding that the selected anti-HLA-G antibodies of the invention bind to certain epitopes of HLA-G with high specificity (no crossreactivity with other species and human HLA-A consensus sequences), and have ability to specifically inhibit ILT2 and or ILT4 binding to HLA-G. They inhibit e.g. ILT2 binding to HLA-G and revert specifically HLA-G mediated immune suppression by increased release of immunomodulatory cytokines like TNF alpha upon appropriate stimulation, and show no effect on HLAG knockout cells.

In certain embodiments, antibodies that bind to HLA-G are provided. Antibodies of the invention are useful, e.g., for the diagnosis or treatment of cancer.

A. Exemplary Anti-HLA-G Antibodies

In one aspect, the invention provide an (isolated) antibody that bind to human HLA-G (anti-HLA-G antibody) and that inhibits ILT2 binding to HLAG on JEG-3 cells (ATCC HTB36) and restores HLA-G specific suppressed immune response (e.g.. suppressed Tumor necrose factor (TNF) alpha release) by monocytes co-cultured with JEG-3 cells (ATCC HTB36). Thus the antibodies of the invention restore a HLAG specific release of TNF alpha in Lipopolysaccharide (LPS) stimulated co-

- 23 -

5 cultures of HLA-G expressing JEG-3 cells (ATCC HTB36) and monocytes compared to untreated co-cultured JEG-3 cells (untreated co-cultures are taken 0% negative reference; monocyte only cultures are taken as 100% positive reference, in which TNF alpha secretion is not suppressed by any HLA-G /IL-T2 specific effects ((see Example 7). In contrast, the antibodies of the present invention are not able to restore the immune response by monocytes co-cultured with JEG3 cell with an HLA-G knock out.

10 One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

15 A) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:3; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6; or

20 B) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:10; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:11; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:12; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:13; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14; or

25 C) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:18; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:19; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:20; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:21; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:22; or

30 D) (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:26; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:27; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:28; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:29; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.

- 24 -

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

- 5 A) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:3; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6; or
- 10 B) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:10, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:11; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:13 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14; or
- 15 C) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:18, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:19; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:20; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:21 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:22; or
- 20 D) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:26, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:27; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:28; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:29 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.
- 25
- 30

- 25 -

One embodiment of the invention is an isolated antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody

A)

- 5
- i) comprises a VH sequence of SEQ ID NO:7 and a VL sequence of SEQ ID NO:8;
 - ii) or humanized variant of the VH and VL of the antibody under i); or
 - iii) comprises a VH sequence of SEQ ID NO:33 and a VL sequence of SEQ ID NO:34; or

10

B)

- i) comprises a VH sequence of SEQ ID NO:15 and a VL sequence of SEQ ID NO:16; or

C)

- 15
- i) comprises a VH sequence of SEQ ID NO:23 and a VL sequence of SEQ ID NO:24; or

D)

- i) comprises a VH sequence of SEQ ID NO:31 and a VL sequence of SEQ ID NO:32.

20

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

- 25
- (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:3; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (e) HVR-L2 comprising the amino

- 26 -

acid sequence of SEQ ID NO:5; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6.

5 One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

10 (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:10; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:11; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:12; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:13; and (f) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14.

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

15 (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:17; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:18; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:19; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:20; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:21; and (f) HVR-L3
20 comprising the amino acid sequence of SEQ ID NO:22.

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

25 (a) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25; (b) HVR-H2 comprising the amino acid sequence of SEQ ID NO:26; (c) HVR-H3 comprising the amino acid sequence of SEQ ID NO:27; (d) HVR-L1 comprising the amino acid sequence of SEQ ID NO:28; (e) HVR-L2 comprising the amino acid sequence of SEQ ID NO:29; and (f) HVR-L3
30 comprising the amino acid sequence of SEQ ID NO:30.

- 27 -

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

- i) a VH sequence of SEQ ID NO:7 and a VL sequence of SEQ ID NO:8;
- 5 ii) or humanized variant of the VH and VL of the antibody under i).

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

- i) a VH sequence of SEQ ID NO:33 and a VL sequence of SEQ ID NO:34.

10 One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

a VH sequence of SEQ ID NO:15 and a VL sequence of SEQ ID NO:16.

15 One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

a VH sequence of SEQ ID NO:23 and a VL sequence of SEQ ID NO:24.

20 One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

a VH sequence of SEQ ID NO:31 and a VL sequence of SEQ ID NO:32.

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

- 25 A) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) HVR-H3 comprising an amino acid sequence SEQ ID NO:3; and wherein the VH domain comprises an amino acid sequence of at least 95%, 96%, 97%, 98%, 99% or 100% (in one preferred embodiment 98% or 99% or

- 28 -

- 100%) sequence identity to the amino acid sequence of SEQ ID NO: 33; and
(b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence
of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID
NO:5 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6;
5 and wherein the VL domain comprises an amino acid sequence of at least 95%,
96%, 97%, 98%, 99% or 100% (in one preferred embodiment 98% or 99% or
100%) sequence identity to the amino acid sequence of SEQ ID NO: 34; or
- B) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence
of SEQ ID NO:9, (ii) HVR-H2 comprising the amino acid sequence of SEQ
10 ID NO:10, and (iii) HVR-H3 comprising an amino acid sequence selected from
SEQ ID NO:11; and wherein the VH domain comprises an amino acid
sequence of at least 95%, 96%, 97%, 98%, 99% or 100% (in one preferred
embodiment 98% or 99% or 100%) sequence identity to the amino acid
sequence of SEQ ID NO: 15; and (b) a VL domain comprising (i) HVR-L1
15 comprising the amino acid sequence of SEQ ID NO:12; (ii) HVR-L2
comprising the amino acid sequence of SEQ ID NO:13 and (iii) HVR-L3
comprising the amino acid sequence of SEQ ID NO:14; and wherein the VL
domain comprises an amino acid sequence of at least 95%, 96%, 97%, 98%,
99% or 100% (in one preferred embodiment 98% or 99% or 100%) sequence
20 identity to the amino acid sequence of SEQ ID NO: 16; or
- C) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence
of SEQ ID NO:17, (ii) HVR-H2 comprising the amino acid sequence of SEQ
ID NO:18, and (iii) HVR-H3 comprising an amino acid sequence selected from
SEQ ID NO:19; and wherein the VH domain comprises an amino acid
25 sequence of at least 95%, 96%, 97%, 98%, 99% or 100% (in one preferred
embodiment 98% or 99% or 100%) sequence identity to the amino acid
sequence of SEQ ID NO: 23; and (b) a VL domain comprising (i) HVR-L1
comprising the amino acid sequence of SEQ ID NO:20; (ii) HVR-L2
comprising the amino acid sequence of SEQ ID NO:21 and (iii) HVR-L3
30 comprising the amino acid sequence of SEQ ID NO:22; and wherein the VL
domain comprises an amino acid sequence of at least 95%, 96%, 97%, 98%,
99% or 100% (in one preferred embodiment 98% or 99% or 100%) sequence
identity to the amino acid sequence of SEQ ID NO: 14; or
- D) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence
35 of SEQ ID NO:25, (ii) HVR-H2 comprising the amino acid sequence of SEQ

- 29 -

5 ID NO:26, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:27; and wherein the VH domain comprises an amino acid sequence of at least 95%, 96%, 97%, 98%, 99% or 100% (in one preferred embodiment 98% or 99% or 100%) sequence identity to the amino acid sequence of SEQ ID NO: 31; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:28; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:29 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30; and wherein the VL domain comprises an amino acid sequence of at least 95%, 96%, 97%, 98%, 99% or 100% (in one preferred embodiment 98% or 99% or 100%) sequence identity to the amino acid sequence of SEQ ID NO: 32.

15 One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

20 a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) HVR-H3 comprising an amino acid sequence SEQ ID NO:3; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6; and

25 wherein the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43 with a binding affinity which is substantially the same as (in one embodiment with a KD value of the binding affinity is reduced at most 10-fold compared to, in one embodiment with a KD value of the binding affinity is reduced at most 5-fold compared to) an antibody comprising a VH sequence of SEQ ID NO:33 and a VL sequence of SEQ ID NO:34 (as determined in surface plasmon resonance assay).

30

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

- 30 -

5 a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) HVR-H3 comprising an amino acid sequence SEQ ID NO:3; and wherein the VH domain comprises an amino acid sequence of at least 95%, 96%, 97%, 98%, 99% or 100% (in one preferred embodiment 98% or 99% or 100%) sequence identity to the amino acid sequence of SEQ ID NO: 33; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6; and wherein the VL domain comprises an amino acid sequence of at least 95%, 96%, 97%, 98%, 99% or 100% (in one preferred embodiment 98% or 99% or 100%) sequence identity to the amino acid sequence of SEQ ID NO: 34;

15 and wherein the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43 with a binding affinity which is substantially the same as (in one embodiment with a KD value of the binding affinity is reduced at most 10-fold compared to, in one embodiment with a KD value of the binding affinity is reduced at most 5-fold compared to) an antibody comprising a VH sequence of SEQ ID NO:33 and a VL sequence of SEQ ID NO:34 (as determined in surface plasmon resonance assay); and or

20 wherein the antibody is characterized independently by the following properties:
the anti-HLA-G antibody

- 25 a) does not crossreact with a modified human HLA-G β 2M MHC I complex comprising SEQ ID NO:44; and/ or
- b) does not crossreact with human HLA-A2 β 2M MHC I complex comprising SEQ ID NO:39 and SEQ ID NO: 37; and/ or
- c) does not crossreact with a mouse H2Kd β 2M MHC I complex comprising SEQ ID NO:45; and/ or
- d) does not crossreact with rat RT1A β 2M MHC I complex comprising SEQ ID NO:47; and/ or
- 30 e) inhibits ILT2 binding to monomeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43); and/or

- 31 -

- f) inhibits ILT2 binding to trimeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43), by more than 50% (in one embodiment by more than 60 %) (when compared to the binding without antibody) (see Example 4b); and/or
- 5 g) inhibits ILT2 binding to monomeric and/or dimeric and/or trimeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43), by more than 50% (in one embodiment by more than 80 %) (when compared to the binding without antibody) (see Example 4b); and/or
- 10 h) inhibits ILT2 binding to (HLA-G on) JEG3 cells (ATCC No. HTB36) (by more than 50 % (in one embodiment by more than 80%)) (when compared to the binding without antibody) (see Example 6); and/or
- 15 i) binds to (HLA-G on) JEG3 cells (ATCC No. HTB36) (see Example 5), and inhibits ILT2 binding to (HLA-G on) JEG3 cells (ATCC No. HTB36) (by more than 50 % (in one embodiment by more than 80%)) (when compared to the binding without antibody) (see Example 6); and/or
- 20 j) inhibits CD8a binding to HLAG by more than 80% (when compared to the binding without antibody) (see e.g Example 4c).; and/or
- k) restores HLA-G specific suppressed immune response (e.g.. suppressed Tumor necrose factor (TNF) alpha release) by monocytes co-cultured with JEG-3 cells (ATCC HTB36).

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody binds to the same epitope as an antibody comprising a VH sequence of SEQ ID NO:33 and a VL sequence of SEQ ID NO:34.

25

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

- 30 a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:10, and (iii) HVR-H3 comprising an amino acid sequence SEQ ID

- 32 -

NO:11; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:13 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14; and

5 wherein the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43 with a binding affinity which is substantially the same as (in one embodiment with a KD value of the binding affinity is reduced at most 10-fold compared to, in one embodiment with a KD value of the binding affinity is reduced at most 5-fold compared to) an antibody comprising a VH sequence
10 of SEQ ID NO:15 and a VL sequence of SEQ ID NO:16 (as determined in surface plasmon resonance assay).

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G
15 (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:10, and (iii) HVR-H3 comprising an amino acid sequence SEQ ID NO:11; and wherein the VH domain comprises an amino acid sequence of at
20 least 95%, 96%, 97%, 98%, 99% or 100% (in one preferred embodiment 98% or 99% or 100%) sequence identity to the amino acid sequence of SEQ ID NO: 15; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:13 and (iii) HVR-L3 comprising the amino acid sequence of
25 SEQ ID NO:14; and wherein the VL domain comprises an amino acid sequence of at least 95%, 96%, 97%, 98%, 99% or 100% (in one preferred embodiment 98% or 99% or 100%) sequence identity to the amino acid sequence of SEQ ID NO: 16;

and wherein the antibody binds to HLA-G β 2M MHC I complex comprising
30 SEQ ID NO: 43 with a binding affinity which is substantially the same as (in one embodiment with a KD value of the binding affinity is reduced at most 10-fold compared to, in one embodiment with a KD value of the binding affinity is reduced at most 5-fold compared to) an antibody comprising a VH sequence

- 33 -

of SEQ ID NO:15 and a VL sequence of SEQ ID NO:16 (as determined in surface plasmon resonance assay); and/or

wherein the antibody is characterized independently by the following properties: the anti-HLA-G antibody

- 5 a) does not crossreact with a modified human HLA-G β 2M MHC I complex comprising SEQ ID NO:44; and/ or
- b) does not crossreact with human HLA-A2 β 2M MHC I complex comprising SEQ ID NO:39 and SEQ ID NO: 37; and/ or
- 10 c) does not crossreact with a mouse H2Kd β 2M MHC I complex comprising SEQ ID NO:45; and/ or
- d) does not crossreact with rat RT1A β 2M MHC I complex comprising SEQ ID NO:47; and/ or
- e) inhibits ILT2 binding to monomeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43); and/or
- 15 f) inhibits ILT2 binding to trimeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43), by more than 50% (in one embodiment by more than 60 %) (when compared to the binding without antibody) (see Example 4b); and/or
- 20 g) inhibits ILT2 binding to monomeric and/or dimeric and/or trimeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43), by more than 50% (in on embodiment by more than 80 %) (when compared to the binding without antibody) (see Example 4b); and/ or
- 25 h) inhibits ILT2 binding to (HLA-G on) JEG3 cells (ATCC No. HTB36) (by more than 50 % (in one embodiment by more than 80%)) (when compared to the binding without antibody) (see Example 6); and/or
- 30 i) binds to (HLA-G on) JEG3 cells (ATCC No. HTB36) (see Example 5), and inhibits ILT2 binding to (HLA-G on) JEG3 cells (ATCC No. HTB36) (by more than 50 % (in one embodiment by more than 80%)) (when compared to the binding without antibody) (see Example 6); and/or

- 34 -

j) inhibits CD8a binding to HLAG by more than 80% (when compared to the binding without antibody) (see e.g Example 4c); and/or

k) restores HLA-G specific suppressed immune response (e.g.. suppressed Tumor necrose factor (TNF) alpha release) by monocytes co-cultured with JEG-3 cells (ATCC HTB36).

5

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody binds to the same epitope as an antibody comprising a VH sequence of SEQ ID NO:15 and a VL sequence of SEQ ID NO:16.

10

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:18, and (iii) HVR-H3 comprising an amino acid sequence SEQ ID NO:19; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:20; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:21 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:22; and

15

20

wherein the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43 with a binding affinity which is substantially the same as (in one embodiment with a KD value of the binding affinity is reduced at most 10-fold compared to, in one embodiment with a KD value of the binding affinity is reduced at most 5-fold compared to) an antibody comprising a VH sequence of SEQ ID NO:23 and a VL sequence of SEQ ID NO:24 (as determined in surface plasmon resonance assay).

25

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

30

- 35 -

5 a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:18, and (iii) HVR-H3 comprising an amino acid sequence SEQ ID NO:19; and wherein the VH domain comprises an amino acid sequence of at least 95%, 96%, 97%, 98%, 99% or 100% (in one preferred embodiment 98% or 99% or 100%) sequence identity to the amino acid sequence of SEQ ID NO: 23; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:20; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:21 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:22; and wherein the VL domain comprises an amino acid sequence of at least 95%, 96%, 97%, 98%, 99% or 100% (in one preferred embodiment 98% or 99% or 100%) sequence identity to the amino acid sequence of SEQ ID NO: 24;

15 and wherein the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43 with a binding affinity which is substantially the same as (in one embodiment with a KD value of the binding affinity is reduced at most 10-fold compared to, in one embodiment with a KD value of the binding affinity is reduced at most 5-fold compared to) an antibody comprising a VH sequence of SEQ ID NO:23 and a VL sequence of SEQ ID NO:24 (as determined in surface plasmon resonance assay); and/or

20 wherein the antibody is characterized independently by the following properties:
the anti-HLA-G antibody

- 25 a) does not crossreact with a modified human HLA-G β 2M MHC I complex comprising SEQ ID NO:44; and/ or
- b) does not crossreact with human HLA-A2 β 2M MHC I complex comprising SEQ ID NO:39 and SEQ ID NO: 37; and/ or
- c) does not crossreact with a mouse H2Kd β 2M MHC I complex comprising SEQ ID NO:45; and/ or
- 30 e) does not crossreact with rat RT1A β 2M MHC I complex comprising SEQ ID NO:47; and/ or
- f) inhibits ILT2 binding to monomeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43); and/or

- 36 -

- g) inhibits ILT2 binding to trimeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43), by more than 50% (in one embodiment by more than 60 %) (when compared to the binding without antibody) (see Example 4b); and/or
- 5 h) inhibits ILT2 binding to monomeric and/or dimeric and/or trimeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43), by more than 50% (in one embodiment by more than 80 %) (when compared to the binding without antibody) (see Example 4b); and/or
- 10 i) inhibits ILT2 binding to (HLA-G on) JEG3 cells (ATCC No. HTB36) (by more than 50 % (in one embodiment by more than 80%)) (when compared to the binding without antibody) (see Example 6); and/or
- 15 j) binds to (HLA-G on) JEG3 cells (ATCC No. HTB36) (see Example 5), and inhibits ILT2 binding to (HLA-G on) JEG3 cells (ATCC No. HTB36) (by more than 50 % (in one embodiment by more than 80%)) (when compared to the binding without antibody) (see Example 6); and/or
- k) inhibits CD8a binding to HLAG by more than 80% (when compared to the binding without antibody) (see e.g Example 4c); and/or
- 20 l) restores HLA-G specific suppressed immune response (e.g.. suppressed Tumor necrose factor (TNF) alpha release) by monocytes co-cultured with JEG-3 cells (ATCC HTB36).

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody binds to the same epitope as an antibody comprising a VH sequence of SEQ ID NO:23 and a VL sequence of SEQ ID NO:24.

25

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

- 30 a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:26, and (iii) HVR-H3 comprising an amino acid sequence SEQ ID

- 37 -

NO:27; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:28; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:29 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30; and

5 wherein the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43 with a binding affinity which is substantially the same as (in one embodiment with a KD value of the binding affinity is reduced at most 10-fold compared to, in one embodiment with a KD value of the binding affinity is reduced at most 5-fold compared to) an antibody comprising a VH sequence
10 of SEQ ID NO:31 and a VL sequence of SEQ ID NO:32 (as determined in surface plasmon resonance assay).

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G
15 G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody comprises

a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:26, and (iii) HVR-H3 comprising an amino acid sequence SEQ ID NO:27; and wherein the VH domain comprises an amino acid sequence of at
20 least 95%, 96%, 97%, 98%, 99% or 100% (in one preferred embodiment 98% or 99% or 100%) sequence identity to the amino acid sequence of SEQ ID NO: 31; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:28; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:29 and (iii) HVR-L3 comprising the amino acid sequence of
25 SEQ ID NO:30; and wherein the VL domain comprises an amino acid sequence of at least 95%, 96%, 97%, 98%, 99% or 100% (in one preferred embodiment 98% or 99% or 100%) sequence identity to the amino acid sequence of SEQ ID NO: 32;

and wherein the antibody binds to HLA-G β 2M MHC I complex comprising
30 SEQ ID NO: 43 with a binding affinity which is substantially the same as (in one embodiment with a KD value of the binding affinity is reduced at most 10-fold compared to, in one embodiment with a KD value of the binding affinity is reduced at most 5-fold compared to) an antibody comprising a VH sequence

- 38 -

of SEQ ID NO:31 and a VL sequence of SEQ ID NO:32 (as determined in surface plasmon resonance assay); and or

wherein the antibody is characterized independently by the following properties:
the anti-HLA-G antibody

- 5 a) does not crossreact with a modified human HLA-G β 2M MHC I complex comprising SEQ ID NO:44; and/ or
- b) does not crossreact with human HLA-A2 β 2M MHC I complex comprising SEQ ID NO:39 and SEQ ID NO: 37; and/ or
- 10 c) does not crossreact with a mouse H2Kd β 2M MHC I complex comprising SEQ ID NO:45; and/ or
- d) does not crossreact with rat RT1A β 2M MHC I complex comprising SEQ ID NO:47; and/ or
- e) inhibits ILT2 binding to monomeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43); and/or
- 15 f) inhibits ILT2 binding to trimeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43), by more than 50% (in one embodiment by more than 60 %) (when compared to the binding without antibody) (see Example 4b); and/or
- 20 g) inhibits ILT2 binding to monomeric and/or dimeric and/or trimeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43), by more than 50% (in on embodiment by more than 80 %) (when compared to the binding without antibody) (see Example 4b); and/ or
- 25 h) inhibits ILT2 binding to (HLA-G on) JEG3 cells (ATCC No. HTB36) (by more than 50 % (in one embodiment by more than 80%)) (when compared to the binding without antibody) (see Example 6); and/or
- 30 i) binds to (HLA-G on) JEG3 cells (ATCC No. HTB36) (see Example 5), and inhibits ILT2 binding to (HLA-G on) JEG3 cells (ATCC No. HTB36) (by more than 50 % (in one embodiment by more than 80%)) (when compared to the binding without antibody) (see Example 6); and/or

- 39 -

- j) inhibits CD8a binding to HLAG by more than 80% (when compared to the binding without antibody) (see e.g Example 4c); and/or
- k) restores HLA-G specific suppressed immune response (e.g.. suppressed Tumor necrose factor (TNF) alpha release) by monocytes co-cultured with JEG-3 cells (ATCC HTB36).

5

One embodiment of the invention is an (isolated) antibody that binds to human HLA-G (in one embodiment the antibody binds to HLA-G β 2M MHC I complex comprising SEQ ID NO: 43), wherein the antibody binds to the same epitope as an antibody comprising a VH sequence of SEQ ID NO:31 and a VL sequence of SEQ ID NO:32.

10

In one embodiment of the invention the antibody is of IgG1 isotype. In one embodiment of the invention the antibody is of IgG1 isotype with mutations L234A, L235A and P329G (numbering according to the EU index of Kabat)

15

In a further aspect, an anti-HLA-G antibody according to any of the above embodiments may incorporate any of the features, singly or in combination, as described in Sections 1-7 below:

1. Antibody Affinity

20

In certain embodiments, an antibody provided herein has a dissociation constant KD of $\leq 1 \mu\text{M}$, $\leq 100 \text{ nM}$, $\leq 10 \text{ nM}$, $\leq 1 \text{ nM}$, $\leq 0.1 \text{ nM}$, $\leq 0.01 \text{ nM}$, or $\leq 0.001 \text{ nM}$ (e.g. 10^{-8} M or less, e.g. from 10^{-8} M to 10^{-13} M , e.g., from 10^{-9} M to 10^{-13} M).

25

In one preferred embodiment, KD is measured using surface plasmon resonance assays using a BIACORE[®] at 25°C with immobilized antigen CM5 chips at ~10 response units (RU). Briefly, carboxymethylated dextran biosensor chips (CM5, BIACORE, Inc.) are activated with *N*-ethyl-*N'*-(3-dimethylaminopropyl)-carbodiimide hydrochloride (EDC) and *N*-hydroxysuccinimide (NHS) according to the supplier's instructions. Antigen is diluted with 10 mM sodium acetate, pH 4.8, to 5 $\mu\text{g/ml}$ (~0.2 μM) before injection at a flow rate of 5 $\mu\text{l/minute}$ to achieve approximately 10 response units (RU) of coupled protein. Following the injection of antigen, 1 M ethanolamine is injected to block unreacted groups. For kinetics measurements, two-fold serial dilutions of Fab (0.78 nM to 500 nM) are injected in PBS with 0.05% polysorbate 20 (TWEEN-20TM) surfactant (PBST) at 25°C at a flow rate of approximately 25 $\mu\text{l/min}$. Association rates (k_{on} or k_a) and dissociation rates

30

- 40 -

(k_{off} or k_d) are calculated using a simple one-to-one Langmuir binding model (BIACORE[®] Evaluation Software version 3.2) by simultaneously fitting the association and dissociation sensorgrams. The equilibrium dissociation constant K_D is calculated as the ratio k_d/k_a ($k_{\text{off}}/k_{\text{on}}$). See, e.g., Chen, Y. et al., J. Mol. Biol. 293 (1999) 865-881. If the on-rate exceeds $10^6 \text{ M}^{-1} \text{ s}^{-1}$ by the surface plasmon resonance assay above, then the on-rate can be determined by using a fluorescent quenching technique that measures the increase or decrease in fluorescence emission intensity (excitation = 295 nm; emission = 340 nm, 16 nm band-pass) at 25°C of a 20 nM anti-antigen antibody (Fab form) in PBS, pH 7.2, in the presence of increasing concentrations of antigen as measured in a spectrometer, such as a stop-flow equipped spectrophotometer (Aviv Instruments) or a 8000-series SLM-AMINCO[™] spectrophotometer (ThermoSpectronic) with a stirred cuvette.

2. Antibody Fragments

In certain embodiments, an antibody provided herein is an antibody fragment. Antibody fragments include, but are not limited to, Fab, Fab', Fab'-SH, F(ab')₂, Fv, and scFv fragments, and other fragments described below. For a review of certain antibody fragments, see Hudson, P.J. et al., Nat. Med. 9 (2003) 129-134. For a review of scFv fragments, see, e.g., Plueckthun, A., In; The Pharmacology of Monoclonal Antibodies, Vol. 113, Rosenburg and Moore (eds.), Springer-Verlag, New York (1994), pp. 269-315; see also WO 93/16185; and U.S. Patent Nos. 5,571,894 and 5,587,458. For discussion of Fab and F(ab')₂ fragments comprising salvage receptor binding epitope residues and having increased in vivo half-life, see U.S. Patent No. 5,869,046.

Diabodies are antibody fragments with two antigen-binding sites that may be bivalent or bispecific. See, for example, EP 0 404 097; WO 1993/01161; Hudson, P.J. et al., Nat. Med. 9 (2003) 129-134; and Holliger, P. et al., Proc. Natl. Acad. Sci. USA 90 (1993) 6444-6448. Triabodies and tetrabodies are also described in Hudson, P.J. et al., Nat. Med. 9 (2003) 129-134).

Single-domain antibodies are antibody fragments comprising all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, a single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No. 6,248,516 B1).

Antibody fragments can be made by various techniques, including but not limited to proteolytic digestion of an intact antibody as well as production by recombinant host cells (e.g. *E. coli* or phage), as described herein.

3. Chimeric and Humanized Antibodies

5 In certain embodiments, an antibody provided herein is a chimeric antibody. Certain chimeric antibodies are described, e.g., in U.S. Patent No. 4,816,567; and Morrison, S.L. et al., Proc. Natl. Acad. Sci. USA 81 (1984) 6851-6855). In one example, a chimeric antibody comprises a non-human variable region (e.g., a variable region derived from a mouse, rat, hamster, rabbit, or non-human primate, such as a monkey)
10 and a human constant region. In a further example, a chimeric antibody is a “class switched” antibody in which the class or subclass has been changed from that of the parent antibody. Chimeric antibodies include antigen-binding fragments thereof.

In certain embodiments, a chimeric antibody is a humanized antibody. Typically, a non-human antibody is humanized to reduce immunogenicity to humans, while
15 retaining the specificity and affinity of the parental non-human antibody. Generally, a humanized antibody comprises one or more variable domains in which HVRs, e.g., CDRs, (or portions thereof) are derived from a non-human antibody, and FRs (or portions thereof) are derived from human antibody sequences. A humanized antibody optionally will also comprise at least a portion of a human constant region.
20 In some embodiments, some FR residues in a humanized antibody are substituted with corresponding residues from a non-human antibody (e.g., the antibody from which the HVR residues are derived), e.g., to restore or improve antibody specificity or affinity.

Humanized antibodies and methods of making them are reviewed, e.g., in Almagro,
25 J.C. and Fransson, J., Front. Biosci. 13 (2008) 1619-1633, and are further described, e.g., in Riechmann, I. et al., Nature 332 (1988) 323-329; Queen, C. et al., Proc. Natl. Acad. Sci. USA 86 (1989) 10029-10033; US Patent Nos. 5, 821,337, 7,527,791, 6,982,321, and 7,087,409; Kashmiri, S.V. et al., Methods 36 (2005) 25-34 (describing SDR (a-CDR) grafting); Padlan, E.A., Mol. Immunol. 28 (1991) 489-
30 498 (describing “resurfacing”); Dall’Acqua, W.F. et al., Methods 36 (2005) 43-60 (describing “FR shuffling”); and Osbourn, J. et al., Methods 36 (2005) 61-68 and Klimka, A. et al., Br. J. Cancer 83 (2000) 252-260 (describing the “guided selection” approach to FR shuffling).

Human framework regions that may be used for humanization include but are not limited to: framework regions selected using the "best-fit" method (see, e.g., Sims, M.J. et al., *J. Immunol.* 151 (1993) 2296-2308; framework regions derived from the consensus sequence of human antibodies of a particular subgroup of light or heavy chain variable regions (see, e.g., Carter, P. et al., *Proc. Natl. Acad. Sci. USA* 89 (1992) 4285-4289; and Presta, L.G. et al., *J. Immunol.* 151 (1993) 2623-2632); human mature (somatically mutated) framework regions or human germline framework regions (see, e.g., Almagro, J.C. and Fransson, J., *Front. Biosci.* 13 (2008) 1619-1633); and framework regions derived from screening FR libraries (see, e.g., Baca, M. et al., *J. Biol. Chem.* 272 (1997) 10678-10684 and Rosok, M.J. et al., *J. Biol. Chem.* 271 (1996) 22611-22618).

4. Human Antibodies

In certain embodiments, an antibody provided herein is a human antibody. Human antibodies can be produced using various techniques known in the art. Human antibodies are described generally in van Dijk, M.A. and van de Winkel, J.G., *Curr. Opin. Pharmacol.* 5 (2001) 368-374 and Lonberg, N., *Curr. Opin. Immunol.* 20 (2008) 450-459.

Human antibodies may be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge. Such animals typically contain all or a portion of the human immunoglobulin loci, which replace the endogenous immunoglobulin loci, or which are present extrachromosomally or integrated randomly into the animal's chromosomes. In such transgenic mice, the endogenous immunoglobulin loci have generally been inactivated. For review of methods for obtaining human antibodies from transgenic animals, see Lonberg, N., *Nat. Biotech.* 23 (2005) 1117-1125. See also, e.g., U.S. Patent Nos. 6,075,181 and 6,150,584 describing XENOMOUSE™ technology; U.S. Patent No. 5,770,429 describing HUMAB® technology; U.S. Patent No. 7,041,870 describing K-M MOUSE® technology, and U.S. Patent Application Publication No. US 2007/0061900, describing VELOCIMOUSE® technology). Human variable regions from intact antibodies generated by such animals may be further modified, e.g., by combining with a different human constant region.

Human antibodies can also be made by hybridoma-based methods. Human myeloma and mouse-human heteromyeloma cell lines for the production of human monoclonal

antibodies have been described. (See, e.g., Kozbor, D., *J. Immunol.* 133 (1984) 3001-3005; Brodeur, B.R. et al., *Monoclonal Antibody Production Techniques and Applications*, Marcel Dekker, Inc., New York (1987), pp. 51-63; and Boerner, P. et al., *J. Immunol.* 147 (1991) 86-95) Human antibodies generated via human B-cell hybridoma technology are also described in Li, J. et al., *Proc. Natl. Acad. Sci. USA* 103 (2006) 3557-3562. Additional methods include those described, for example, in U.S. Patent No. 7,189,826 (describing production of monoclonal human IgM antibodies from hybridoma cell lines) and Ni, J., *Xiandai Mianyixue* 26 (2006) 265-268 (describing human-human hybridomas). Human hybridoma technology (Trioma technology) is also described in Vollmers, H.P. and Brandlein, S., *Histology and Histopathology* 20 (2005) 927-937 and Vollmers, H.P. and Brandlein, S., *Methods and Findings in Experimental and Clinical Pharmacology* 27 (2005) 185-191.

Human antibodies may also be generated by isolating Fv clone variable domain sequences selected from human-derived phage display libraries. Such variable domain sequences may then be combined with a desired human constant domain. Techniques for selecting human antibodies from antibody libraries are described below.

5. Library-Derived Antibodies

Antibodies of the invention may be isolated by screening combinatorial libraries for antibodies with the desired activity or activities. For example, a variety of methods are known in the art for generating phage display libraries and screening such libraries for antibodies possessing the desired binding characteristics. Such methods are reviewed, e.g., in Hoogenboom, H.R. et al., *Methods in Molecular Biology* 178 (2001) 1-37 and further described, e.g., in the McCafferty, J. et al., *Nature* 348 (1990) 552-554; Clackson, T. et al., *Nature* 352 (1991) 624-628; Marks, J.D. et al., *J. Mol. Biol.* 222 (1992) 581-597; Marks, J.D. and Bradbury, A., *Methods in Molecular Biology* 248 (2003) 161-175; Sidhu, S.S. et al., *J. Mol. Biol.* 338 (2004) 299-310; Lee, C.V. et al., *J. Mol. Biol.* 340 (2004) 1073-1093; Fellouse, F.A., *Proc. Natl. Acad. Sci. USA* 101 (2004) 12467-12472; and Lee, C.V. et al., *J. Immunol. Methods* 284 (2004) 119-132.

In certain phage display methods, repertoires of VH and VL genes are separately cloned by polymerase chain reaction (PCR) and recombined randomly in phage libraries, which can then be screened for antigen-binding phage as described in Winter, G. et al., *Ann. Rev. Immunol.* 12 (1994) 433-455. Phage typically display

antibody fragments, either as single-chain Fv (scFv) fragments or as Fab fragments. Libraries from immunized sources provide high-affinity antibodies to the immunogen without the requirement of constructing hybridomas. Alternatively, the naive repertoire can be cloned (e.g., from human) to provide a single source of antibodies to a wide range of non-self and also self antigens without any immunization as described by Griffiths, A.D. et al., EMBO J. 12 (1993) 725-734. Finally, naive libraries can also be made synthetically by cloning non-rearranged V-gene segments from stem cells, and using PCR primers containing random sequence to encode the highly variable CDR3 regions and to accomplish rearrangement *in vitro*, as described by Hoogenboom, H.R. and Winter, G., J. Mol. Biol. 227 (1992) 381-388. Patent publications describing human antibody phage libraries include, for example: US Patent No. 5,750,373, and US Patent Publication Nos. 2005/0079574, 2005/0119455, 2005/0266000, 2007/0117126, 2007/0160598, 2007/0237764, 2007/0292936, and 2009/0002360.

Antibodies or antibody fragments isolated from human antibody libraries are considered human antibodies or human antibody fragments herein.

6. Multispecific Antibodies

In certain embodiments, an antibody provided herein is a multispecific antibody, e.g. a bispecific antibody. Multispecific antibodies are monoclonal antibodies that have binding specificities for at least two different sites. In certain embodiments, one of the binding specificities is for HLA-G and the other is for any other antigen. Bispecific antibodies can be prepared as full length antibodies or antibody fragments.

Techniques for making multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs having different specificities (see Milstein, C. and Cuello, A.C., Nature 305 (1983) 537-540, WO 93/08829, and Traunecker, A. et al., EMBO J. 10 (1991) 3655-3659), and "knob-in-hole" engineering (see, e.g., U.S. Patent No. 5,731,168). Multi-specific antibodies may also be made by engineering electrostatic steering effects for making antibody Fc-heterodimeric molecules (WO 2009/089004); cross-linking two or more antibodies or fragments (see, e.g., US Patent No. 4,676,980, and Brennan, M. et al., Science 229 (1985) 81-83); using leucine zippers to produce bi-specific antibodies (see, e.g., Kostelny, S.A. et al., J. Immunol. 148 (1992) 1547-1553; using "diabody" technology for making bispecific antibody fragments (see, e.g., Holliger, P. et al., Proc. Natl. Acad. Sci. USA 90 (1993) 6444-6448); and using single-chain Fv (sFv)

- 45 -

dimers (see, e.g. Gruber, M et al., J. Immunol. 152 (1994) 5368-5374); and preparing trispecific antibodies as described, e.g., in Tutt, A. et al., J. Immunol. 147 (1991) 60-69).

5 Engineered antibodies with three or more functional antigen binding sites, including “Octopus antibodies,” are also included herein (see, e.g. US 2006/0025576).

The antibody or fragment herein also includes a “Dual Acting Fab” or “DAF” comprising an antigen binding site that binds to HLA-G as well as another, different antigen (see, US 2008/0069820, for example).

10 The antibody or fragment herein also includes multispecific antibodies described in WO 2009/080251, WO 2009/080252, WO 2009/080253, WO 2009/080254, WO 2010/112193, WO 2010/115589, WO 2010/136172, WO 2010/145792, and WO 2010/145793, WO2011/117330, WO2012/025525, WO2012/025530, WO2013/026835, WO2013/026831, WO2013/164325, or WO 2013/174873.

7. Antibody Variants

15 In certain embodiments, amino acid sequence variants of the antibodies provided herein are contemplated. For example, it may be desirable to improve the binding affinity and/or other biological properties of the antibody. Amino acid sequence variants of an antibody may be prepared by introducing appropriate modifications into the nucleotide sequence encoding the antibody, or by peptide synthesis. Such
20 modifications include, for example, deletions from, and/or insertions into and/or substitutions of residues within the amino acid sequences of the antibody. Any combination of deletion, insertion, and substitution can be made to arrive at the final construct, provided that the final construct possesses the desired characteristics, e.g., antigen-binding.

25 a)Substitution, Insertion, and Deletion Variants

In certain embodiments, antibody variants having one or more amino acid substitutions are provided. Sites of interest for substitutional mutagenesis include the HVRs and FRs. Exemplary changes are provided in Table 1 under the heading of "exemplary substitutions", and as further described below in reference to amino acid
30 side chain classes. Conservative substitutions are shown in Table 1 under the heading of "preferred substitutions". Amino acid substitutions may be introduced into an antibody of interest and the products screened for a desired activity, e.g.,

retained/improved antigen binding, decreased immunogenicity, or improved ADCC or CDC.

Table 1

Original Residue	Exemplary Substitutions	Preferred Substitutions
Ala (A)	Val; Leu; Ile	Val
Arg (R)	Lys; Gln; Asn	Lys
Asn (N)	Gln; His; Asp, Lys; Arg	Gln
Asp (D)	Glu; Asn	Glu
Cys (C)	Ser; Ala	Ser
Gln (Q)	Asn; Glu	Asn
Glu (E)	Asp; Gln	Asp
Gly (G)	Ala	Ala
His (H)	Asn; Gln; Lys; Arg	Arg
Ile (I)	Leu; Val; Met; Ala; Phe; Norleucine	Leu
Leu (L)	Norleucine; Ile; Val; Met; Ala; Phe	Ile
Lys (K)	Arg; Gln; Asn	Arg
Met (M)	Leu; Phe; Ile	Leu
Phe (F)	Trp; Leu; Val; Ile; Ala; Tyr	Tyr
Pro (P)	Ala	Ala
Ser (S)	Thr	Thr
Thr (T)	Val; Ser	Ser
Trp (W)	Tyr; Phe	Tyr
Tyr (Y)	Trp; Phe; Thr; Ser	Phe
Val (V)	Ile; Leu; Met; Phe; Ala; Norleucine	Leu

5 Amino acids may be grouped according to common side-chain properties:

- (1) hydrophobic: Norleucine, Met, Ala, Val, Leu, Ile;
- (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;
- (3) acidic: Asp, Glu;

- 47 -

(4) basic: His, Lys, Arg;

(5) residues that influence chain orientation: Gly, Pro;

(6) aromatic: Trp, Tyr, Phe.

5 Non-conservative substitutions will entail exchanging a member of one of these classes for another class.

10 One type of substitutional variant involves substituting one or more hypervariable region residues of a parent antibody (e.g. a humanized or human antibody). Generally, the resulting variant(s) selected for further study will have modifications (e.g., improvements) in certain biological properties (e.g., increased affinity, reduced immunogenicity) relative to the parent antibody and/or will have substantially retained certain biological properties of the parent antibody. An exemplary substitutional variant is an affinity matured antibody, which may be conveniently generated, e.g., using phage display-based affinity maturation techniques such as those described herein. Briefly, one or more HVR residues are mutated and the variant antibodies displayed on phage and screened for a particular biological activity (e.g. binding affinity).

15 Alterations (e.g., substitutions) may be made in HVRs, e.g., to improve antibody affinity. Such alterations may be made in HVR “hotspots,” i.e., residues encoded by codons that undergo mutation at high frequency during the somatic maturation process (see, e.g., Chowdhury, P.S., *Methods Mol. Biol.* 207 (2008) 179-196), and/or SDRs (a-CDRs), with the resulting variant VH or VL being tested for binding affinity. Affinity maturation by constructing and reselecting from secondary libraries has been described, e.g., in Hoogenboom, H.R. et al. in *Methods in Molecular Biology* 178 (2002) 1-37. In some embodiments of affinity maturation, diversity is introduced into the variable genes chosen for maturation by any of a variety of methods (e.g., error-prone PCR, chain shuffling, or oligonucleotide-directed mutagenesis). A secondary library is then created. The library is then screened to identify any antibody variants with the desired affinity. Another method to introduce diversity involves HVR-directed approaches, in which several HVR residues (e.g., 20 4-6 residues at a time) are randomized. HVR residues involved in antigen binding may be specifically identified, e.g., using alanine scanning mutagenesis or modeling. CDR-H3 and CDR-L3 in particular are often targeted.

25

30

- 48 -

In certain embodiments, substitutions, insertions, or deletions may occur within one or more HVRs so long as such alterations do not substantially reduce the ability of the antibody to bind antigen. For example, conservative alterations (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity may be made in HVRs. Such alterations may be outside of HVR “hotspots” or SDRs. In certain embodiments of the variant VH and VL sequences provided above, each HVR either is unaltered, or contains no more than one, two or three amino acid substitutions.

A useful method for identification of residues or regions of an antibody that may be targeted for mutagenesis is called "alanine scanning mutagenesis" as described by Cunningham, B.C. and Wells, J.A., Science 244 (1989) 1081-1085. In this method, a residue or group of target residues (e.g., charged residues such as arg, asp, his, lys, and glu) are identified and replaced by a neutral or negatively charged amino acid (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with antigen is affected. Further substitutions may be introduced at the amino acid locations demonstrating functional sensitivity to the initial substitutions. Alternatively, or additionally, a crystal structure of an antigen-antibody complex to identify contact points between the antibody and antigen. Such contact residues and neighboring residues may be targeted or eliminated as candidates for substitution. Variants may be screened to determine whether they contain the desired properties.

Amino acid sequence insertions include amino- and/or carboxyl-terminal fusions ranging in length from one residue to polypeptides containing a hundred or more residues, as well as intrasequence insertions of single or multiple amino acid residues. Examples of terminal insertions include an antibody with an N-terminal methionyl residue. Other insertional variants of the antibody molecule include the fusion to the N- or C-terminus of the antibody to an enzyme (e.g. for ADEPT) or a polypeptide which increases the serum half-life of the antibody.

b) Fc region variants

In certain embodiments, one or more amino acid modifications may be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (e.g., a human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g. a substitution) at one or more amino acid positions.

Antibodies with reduced effector function include those with substitution of one or more of Fc region residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Patent No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more of amino acid positions 265, 269, 270, 297 and 327, including the so-called “DANA”
5 Fc mutant with substitution of residues 265 and 297 to alanine (US Patent No. 7,332,581).

Certain antibody variants with improved or diminished binding to FcRs are described. (See, e.g., U.S. Patent No. 6,737,056; WO 2004/056312, and Shields, R.L. et al., *J. Biol. Chem.* 276 (2001) 6591-6604).

10 In one embodiment the invention such antibody is a IgG1 with mutations L234A and L235A or with mutations L234A, L235A and P329G. In another embodiment or IgG4 with mutations S228P and L235E or S228P, L235E or and P329G (numbering according to EU index of Kabat et al, Kabat et al., *Sequences of Proteins of Immunological Interest*, 5th Ed. Public Health Service, National Institutes of Health,
15 Bethesda, MD, 1991).

Antibodies with increased half lives and improved binding to the neonatal Fc receptor (FcRn), which is responsible for the transfer of maternal IgGs to the fetus (Guyer, R.L. et al., *J. Immunol.* 117 (1976) 587-593, and Kim, J.K. et al., *J. Immunol.* 24 (1994) 2429-2434), are described in US 2005/0014934. Those antibodies
20 comprise an Fc region with one or more substitutions therein which improve binding of the Fc region to FcRn. Such Fc variants include those with substitutions at one or more of Fc region residues: 238, 256, 265, 272, 286, 303, 305, 307, 311, 312, 317, 340, 356, 360, 362, 376, 378, 380, 382, 413, 424 or 434, e.g., substitution of Fc region residue 434 (US Patent No. 7,371,826).

25 See also Duncan, A.R. and Winter, G., *Nature* 322 (1988) 738-740; US 5,648,260; US 5,624,821; and WO 94/29351 concerning other examples of Fc region variants.

c) Cysteine engineered antibody variants

In certain embodiments, it may be desirable to create cysteine engineered antibodies, e.g., “thioMAbs,” in which one or more residues of an antibody are substituted with
30 cysteine residues. In particular embodiments, the substituted residues occur at accessible sites of the antibody. By substituting those residues with cysteine, reactive thiol groups are thereby positioned at accessible sites of the antibody and may be used to conjugate the antibody to other moieties, such as drug moieties or linker-

- 50 -

drug moieties, to create an immunoconjugate, as described further herein. In certain embodiments, any one or more of the following residues may be substituted with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) of the heavy chain Fc region. Cysteine engineered antibodies may be generated as described, e.g., in U.S. Patent No. 7,521,541.

d) Antibody Derivatives

In certain embodiments, an antibody provided herein may be further modified to contain additional non-proteinaceous moieties that are known in the art and readily available. The moieties suitable for derivatization of the antibody include but are not limited to water soluble polymers. Non-limiting examples of water soluble polymers include, but are not limited to, polyethylene glycol (PEG), copolymers of ethylene glycol/propylene glycol, carboxymethylcellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1, 3-dioxolane, poly-1,3,6-trioxane, ethylene/maleic anhydride copolymer, polyaminoacids (either homopolymers or random copolymers), and dextran or poly(n-vinyl pyrrolidone)polyethylene glycol, propylene glycol homopolymers, polypropylene oxide/ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Polyethylene glycol propionaldehyde may have advantages in manufacturing due to its stability in water. The polymer may be of any molecular weight, and may be branched or unbranched. The number of polymers attached to the antibody may vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and/or type of polymers used for derivatization can be determined based on considerations including, but not limited to, the particular properties or functions of the antibody to be improved, whether the antibody derivative will be used in a therapy under defined conditions, etc.

In another embodiment, conjugates of an antibody and non-proteinaceous moiety that may be selectively heated by exposure to radiation are provided. In one embodiment, the non-proteinaceous moiety is a carbon nanotube (Kam, N.W. et al., Proc. Natl. Acad. Sci. USA 102 (2005) 11600-11605). The radiation may be of any wavelength, and includes, but is not limited to, wavelengths that do not harm ordinary cells, but which heat the non-proteinaceous moiety to a temperature at which cells proximal to the antibody-non-proteinaceous moiety are killed.

B. Recombinant Methods and Compositions

Antibodies may be produced using recombinant methods and compositions, e.g., as described in U.S. Patent No. 4,816,567. In one embodiment, isolated nucleic acid encoding an anti-HLA-G antibody described herein is provided. Such nucleic acid may encode an amino acid sequence comprising the VL and/or an amino acid sequence comprising the VH of the antibody (e.g., the light and/or heavy chains of the antibody). In a further embodiment, one or more vectors (e.g., expression vectors) comprising such nucleic acid are provided. In a further embodiment, a host cell comprising such nucleic acid is provided. In one such embodiment, a host cell comprises (e.g., has been transformed with): (1) a vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and an amino acid sequence comprising the VH of the antibody, or (2) a first vector comprising a nucleic acid that encodes an amino acid sequence comprising the VL of the antibody and a second vector comprising a nucleic acid that encodes an amino acid sequence comprising the VH of the antibody. In one embodiment, the host cell is eukaryotic, e.g. a Chinese Hamster Ovary (CHO) cell, a HEK293 cell or lymphoid cell (e.g., Y0, NS0, Sp20 cell). In one embodiment, a method of making an anti-HLA-G antibody is provided, wherein the method comprises culturing a host cell comprising a nucleic acid encoding the antibody, as provided above, under conditions suitable for expression of the antibody, and optionally recovering the antibody from the host cell (or host cell culture medium).

For recombinant production of an anti-HLA-G antibody, nucleic acid encoding an antibody, e.g., as described above, is isolated and inserted into one or more vectors for further cloning and/or expression in a host cell. Such nucleic acid may be readily isolated and sequenced using conventional procedures (e.g., by using oligonucleotide probes that are capable of binding specifically to genes encoding the heavy and light chains of the antibody).

Suitable host cells for cloning or expression of antibody-encoding vectors include prokaryotic or eukaryotic cells described herein. For example, antibodies may be produced in bacteria, in particular when glycosylation and Fc effector function are not needed. For expression of antibody fragments and polypeptides in bacteria, see, e.g., US 5,648,237, US 5,789,199, and US 5,840,523. (See also Charlton, K.A., In: *Methods in Molecular Biology*, Vol. 248, Lo, B.K.C. (ed.), Humana Press, Totowa, NJ (2003), pp. 245-254, describing expression of antibody fragments in *E. coli*.)

After expression, the antibody may be isolated from the bacterial cell paste in a soluble fraction and can be further purified.

In addition to prokaryotes, eukaryotic microbes such as filamentous fungi or yeast are suitable cloning or expression hosts for antibody-encoding vectors, including
5 fungi and yeast strains whose glycosylation pathways have been “humanized,” resulting in the production of an antibody with a partially or fully human glycosylation pattern. See Gerngross, T.U., Nat. Biotech. 22 (2004) 1409-1414; and Li, H. et al., Nat. Biotech. 24 (2006) 210-215.

Suitable host cells for the expression of glycosylated antibody are also derived from
10 multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculoviral strains have been identified which may be used in conjunction with insect cells, particularly for transfection of *Spodoptera frugiperda* cells.

Plant cell cultures can also be utilized as hosts. See, e.g., US Patent Nos. 5,959,177,
15 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES™ technology for producing antibodies in transgenic plants).

Vertebrate cells may also be used as hosts. For example, mammalian cell lines that are adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-
20 7); human embryonic kidney line (293 or 293 cells as described, e.g., in Graham, F.L. et al., J. Gen Virol. 36 (1977) 59-74); baby hamster kidney cells (BHK); mouse sertoli cells (TM4 cells as described, e.g., in Mather, J.P., Biol. Reprod. 23 (1980) 243-252); monkey kidney cells (CV1); African green monkey kidney cells (VERO-76); human cervical carcinoma cells (HELA); canine kidney cells (MDCK; buffalo
25 rat liver cells (BRL 3A); human lung cells (W138); human liver cells (Hep G2); mouse mammary tumor (MMT 060562); TRI cells, as described, e.g., in Mather, J.P. et al., Annals N.Y. Acad. Sci. 383 (1982) 44-68; MRC 5 cells; and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including DHFR⁻ CHO cells (Urlaub, G. et al., Proc. Natl. Acad. Sci. USA 77 (1980)
30 4216-4220); and myeloma cell lines such as Y0, NS0 and Sp2/0. For a review of certain mammalian host cell lines suitable for antibody production, see, e.g., Yazaki, P. and Wu, A.M., Methods in Molecular Biology, Vol. 248, Lo, B.K.C. (ed.), Humana Press, Totowa, NJ (2004), pp. 255-268.

C. Assays

5 Anti-HLA-G antibodies provided herein may be identified, screened for, or characterized for their physical/chemical properties and/or biological activities by various assays known in the art.

1. Binding assays and other assays

In one aspect, an antibody of the invention is tested for its antigen binding activity, e.g., by known methods such as ELISA, Western blot, etc.

10 In another aspect, competition assays may be used to identify an antibody that competes with HLA-G-0031 (comprising a VH sequence of SEQ ID NO:7 and a VL sequence of SEQ ID NO:8) for binding to HLA-G. One embodiment of the invention is an antibody which competes for binding to human HLA-G with an anti-HLA-G antibody comprising all 3 HVRs of VH sequence of SEQ ID NO:7 and all 3 HVRs of VL sequence of SEQ ID NO:8. In certain embodiments, such a competing antibody binds to the same epitope (e.g., a linear or a conformational epitope) that is bound by anti-HLA-G antibody HLA-G-0031. In one embodiment an anti-HLA-G antibody is provide which binds to the same epitope on HLA-G as an antibody comprising a VH sequence of SEQ ID NO:7 and a VL sequence of SEQ ID NO:8.

15 In another aspect, competition assays may be used to identify an antibody that competes with HLA-G-0090 (comprising a VH sequence of SEQ ID NO:31 and a VL sequence of SEQ ID NO:32) for binding to HLA-G. One embodiment of the invention is an antibody which competes for binding to human HLA-G with an anti-HLA-G antibody comprising all 3 HVRs of VH sequence of SEQ ID NO:31 and all 3 HVRs of VL sequence of SEQ ID NO:32. In certain embodiments, such a competing antibody binds to the same epitope (e.g., a linear or a conformational epitope) that is bound by anti-HLA-G antibody HLA-G-0090. In one embodiment an anti-HLA-G antibody is provide which binds to the same epitope on HLA-G as an antibody comprising a VH sequence of SEQ ID NO:31 and a VL sequence of SEQ ID NO:32. Detailed exemplary methods for mapping an epitope to which an antibody binds are provided in Morris, G.E. (ed.), Epitope Mapping Protocols, In: Methods in Molecular Biology, Vol. 66, Humana Press, Totowa, NJ (1996).

20
25
30

In an exemplary competition assay, immobilized HLA-G is incubated in a solution comprising a first labeled antibody that binds to HLA-G (e.g., anti- HLA-G antibody HLA-G-0031 or HLA-G-0090) and a second unlabeled antibody that is being tested

- 54 -

for its ability to compete with the first antibody for binding to HLA-G. The second antibody may be present in a hybridoma supernatant. As a control, immobilized HLA-G is incubated in a solution comprising the first labeled antibody but not the second unlabeled antibody. After incubation under conditions permissive for binding of the first antibody to HLA-G, excess unbound antibody is removed, and the amount of label associated with immobilized HLA-G is measured. If the amount of label associated with immobilized HLA-G is substantially reduced in the test sample relative to the control sample, then that indicates that the second antibody is competing with the first antibody for binding to HLA-G. See Harlow, E. and Lane, D., *Antibodies: A Laboratory Manual*, Chapter 14, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY (1988). For another exemplary competition assay see Example 2 (Epitope mapping ELISA/ Binding competition assay).

2. Activity assays

In one aspect, assays are provided for identifying anti-HLA-G antibodies thereof having biological activity. Biological activity may include, e.g., the ability to enhance the activation and/or proliferation of different immune cells including T-cells. E.g. they enhance release of immunomodulating cytokines (e.g. interferon-gamma (IFN-gamma) and/or tumor necrosis factor alpha (TNF alpha)). Other immunomodulating cytokines which are or can be enhance are e.g. IL1 β , IL6, IL12, Granzyme B etc. binding to different cell types. Antibodies having such biological activity in vivo and/or in vitro are also provided.

In certain embodiments, an antibody of the invention is tested for such biological activity as described e.g. in Examples below.

D. Immunoconjugates (Cancer only or modify for target)

The invention also provides immunoconjugates comprising an anti-HLA-G antibody herein conjugated to one or more cytotoxic agents, such as chemotherapeutic agents or drugs, growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), or radioactive isotopes.

In one embodiment, an immunoconjugate is an antibody-drug conjugate (ADC) in which an antibody is conjugated to one or more drugs, including but not limited to a maytansinoid (see US 5,208,020, US 5,416,064 and EP 0 425 235 B1); an auristatin such as monomethyl auristatin drug moieties DE and DF (MMAE and MMAF) (see

US 5,635,483, US 5,780,588, and US 7,498,298); a dolastatin; a calicheamicin or derivative thereof (see US 5,712,374, US 5,714,586, US 5,739,116, US 5,767,285, US 5,770,701, US 5,770,710, US 5,773,001, and US 5,877,296; Hinman, L.M. et al., Cancer Res. 53 (1993) 3336-3342; and Lode, H.N. et al., Cancer Res. 58 (1998) 2925-2928); an anthracycline such as daunomycin or doxorubicin (see Kratz, F. et al., Curr. Med. Chem. 13 (2006) 477-523; Jeffrey, S.C. et al., Bioorg. Med. Chem. Lett. 16 (2006) 358-362; Torgov, M.Y. et al., Bioconjug. Chem. 16 (2005) 717-721; Nagy, A. et al., Proc. Natl. Acad. Sci. USA 97 (2000) 829-834; Dubowchik, G.M. et al., Bioorg. & Med. Chem. Letters 12 (2002) 1529-1532; King, H.D. et al., J. Med. Chem. 45 (2002) 4336-4343; and U.S. Patent No. 6,630,579); methotrexate; vindesine; a taxane such as docetaxel, paclitaxel, larotaxel, tesetaxel, and ortataxel; a trichothecene; and CC1065.

In another embodiment, an immunoconjugate comprises an antibody as described herein conjugated to an enzymatically active toxin or fragment thereof, including but not limited to diphtheria A chain, nonbinding active fragments of diphtheria toxin, exotoxin A chain (from *Pseudomonas aeruginosa*), ricin A chain, abrin A chain, modeccin A chain, alpha-sarcin, *Aleurites fordii* proteins, dianthin proteins, *Phytolaca americana* proteins (PAPI, PAPII, and PAP-S), momordica charantia inhibitor, curcin, crotin, *saponaria officinalis* inhibitor, gelonin, mitogellin, restrictocin, phenomycin, enomycin, and the tricothecenes.

In another embodiment, an immunoconjugate comprises an antibody as described herein conjugated to a radioactive atom to form a radioconjugate. A variety of radioactive isotopes are available for the production of radioconjugates. Examples include At²¹¹, I¹³¹, I¹²⁵, Y⁹⁰, Re¹⁸⁶, Re¹⁸⁸, Sm¹⁵³, Bi²¹², P³², Pb²¹² and radioactive isotopes of Lu. When the radioconjugate is used for detection, it may comprise a radioactive atom for scintigraphic studies, for example TC^{99m} or I¹²³, or a spin label for nuclear magnetic resonance (NMR) imaging (also known as magnetic resonance imaging, MRI), such as iodine-123 again, iodine-131, indium-111, fluorine-19, carbon-13, nitrogen-15, oxygen-17, gadolinium, manganese or iron.

Conjugates of an antibody and cytotoxic agent may be made using a variety of bifunctional protein coupling agents such as N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP), succinimidyl-4-(N-maleimidomethyl) cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis (p-

- 56 -

azidobenzoyl) hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (such as 1,5-difluoro-2,4-dinitrobenzene). For example, a ricin immunotoxin can be prepared as described in
5 Vitetta, E.S. et al., Science 238 (1987) 1098-1104. Carbon-14-labeled 1-isothiocyanatobenzyl-3-methyldiethylene triamine pentaacetic acid (MX-DTPA) is an exemplary chelating agent for conjugation of radionucleotide to the antibody. See WO 94/11026. The linker may be a “cleavable linker” facilitating release of a cytotoxic drug in the cell. For example, an acid-labile linker, peptidase-sensitive
10 linker, photolabile linker, dimethyl linker or disulfide-containing linker (Chari, R.V. et al., Cancer Res. 52 (1992) 127-131; U.S. Patent No. 5,208,020) may be used.

The immunuoconjugates or ADCs herein expressly contemplate, but are not limited to such conjugates prepared with cross-linker reagents including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB,
15 SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and SVSB (succinimidyl-(4-vinylsulfone)benzoate) which are commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, IL., U.S.A).

E. Methods and Compositions for Diagnostics and Detection

20 In certain embodiments, any of the anti-HLA-G antibodies provided herein is useful for detecting the presence of HLA-G in a biological sample. The term “detecting” as used herein encompasses quantitative or qualitative detection. In certain embodiments, a biological sample comprises a cell or tissue, such as immune cell or
25 T cell infiltrates and or tumor cells.

In one embodiment, an anti-HLA-G antibody for use in a method of diagnosis or detection is provided. In a further aspect, a method of detecting the presence of HLA-G in a biological sample is provided. In certain embodiments, the method comprises contacting the biological sample with an anti-HLA-G antibody as described herein
30 under conditions permissive for binding of the anti-HLA-G antibody to HLA-G, and detecting whether a complex is formed between the anti-HLA-G antibody and HLA-G. Such method may be an *in vitro* or *in vivo* method. In one embodiment, an anti-HLA-G antibody is used to select subjects eligible for therapy with an anti-HLA-G antibody, e.g. where HLA-G is a biomarker for selection of patients.

- 57 -

In certain embodiments, labeled anti-HLA-G antibodies are provided. Labels include, but are not limited to, labels or moieties that are detected directly (such as fluorescent, chromophoric, electron-dense, chemiluminescent, and radioactive labels), as well as moieties, such as enzymes or ligands, that are detected indirectly, e.g., through an enzymatic reaction or molecular interaction. Exemplary labels include, but are not limited to, the radioisotopes ^{32}P , ^{14}C , ^{125}I , ^3H , and ^{131}I , fluorophores such as rare earth chelates or fluorescein and its derivatives, rhodamine and its derivatives, dansyl, umbelliferone, luciferases, e.g., firefly luciferase and bacterial luciferase (U.S. Patent No. 4,737,456), luciferin, 2,3-dihydrophthalazinediones, horseradish peroxidase (HRP), alkaline phosphatase, β -galactosidase, glucoamylase, lysozyme, saccharide oxidases, e.g., glucose oxidase, galactose oxidase, and glucose-6-phosphate dehydrogenase, heterocyclic oxidases such as uricase and xanthine oxidase, coupled with an enzyme that employs hydrogen peroxide to oxidize a dye precursor such as HRP, lactoperoxidase, or microperoxidase, biotin/avidin, spin labels, bacteriophage labels, stable free radicals, and the like.

F. Pharmaceutical Formulations

Pharmaceutical formulations of an anti-HLA-G antibody as described herein are prepared by mixing such antibody having the desired degree of purity with one or more optional pharmaceutically acceptable carriers (Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed.) (1980)), in the form of lyophilized formulations or aqueous solutions. Pharmaceutically acceptable carriers are generally nontoxic to recipients at the dosages and concentrations employed, and include, but are not limited to: buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyl dimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as poly(vinylpyrrolidone); amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrans; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g. Zn-protein complexes); and/or non-ionic

- 58 -

5 surfactants such as polyethylene glycol (PEG). Exemplary pharmaceutically acceptable carriers herein further include interstitial drug dispersion agents such as soluble neutral-active hyaluronidase glycoproteins (sHASEGP), for example, human soluble PH-20 hyaluronidase glycoproteins, such as rhuPH20 (HYLENEX[®], Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use, including rhuPH20, are described in US Patent Publication Nos. 2005/0260186 and 2006/0104968. In one aspect, a sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.

10 Exemplary lyophilized antibody formulations are described in US Patent No. 6,267,958. Aqueous antibody formulations include those described in US Patent No. 6,171,586 and WO 2006/044908, the latter formulations including a histidine-acetate buffer.

15 The formulation herein may also contain more than one active ingredients as necessary for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. For example, it may be desirable to further provide. Such active ingredients are suitably present in combination in amounts that are effective for the purpose intended.

20 Active ingredients may be entrapped in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization, for example, hydroxymethylcellulose or gelatin-microcapsules and poly- (methyl methacrylate) microcapsules, respectively, in colloidal drug delivery systems (for example, liposomes, albumin microspheres, microemulsions, nano-particles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed.) (1980).

25 Sustained-release preparations may be prepared. Suitable examples of sustained-release preparations include semi-permeable matrices of solid hydrophobic polymers containing the antibody, which matrices are in the form of shaped articles, *e.g.* films, or microcapsules.

30 The formulations to be used for *in vivo* administration are generally sterile. Sterility may be readily accomplished, *e.g.*, by filtration through sterile filtration membranes.

G. Therapeutic Methods and Compositions

Any of the anti-HLA-G antibodies (or antigen binding proteins) provided herein may be used in therapeutic methods.

5 In one aspect, an anti-HLA-G antibody for use as a medicament is provided. In further aspects, an anti-HLA-G antibody or use in treating cancer is provided. In certain embodiments, an anti-HLA-G antibody for use in a method of treatment is provided. In certain embodiments, the invention provides an anti-HLA-G antibody for use in a method of treating an individual having cancer comprising administering
10 to the individual an effective amount of the anti-HLA-G antibody.

In further embodiments, the invention provides an anti-HLA-G antibody for use as immunomodulatory agent/ to directly or indirectly induce proliferation, activation of immune cells (e.g. by release of immunostimulatory cytokines like TNFalpha (TNFa) and IFNgamma (IFNg) or further recruitment of immune cells. In certain
15 embodiments, the invention provides an anti-HLA-G antibody for use in a method of immunomodulatory agent/ to directly or indirectly induce proliferation, activation of immune cells e.g. by release of immunostimulatory cytokines like TNFa and IFNgamma or further recruitment of immune cells in an individual comprising administering to the individual an effective of the anti-HLA-G antibody for
20 immunomodulation/ or directly or indirectly induce proliferation, activation of immune cells e.g. by release of immunostimulatory cytokines like TNFa and IFNgamma or further recruitment of immune cells.

In further embodiments, the invention provides an anti-HLA-G antibody for use as immunostimulatory agent/or stimulating tumor necrosis factor alpha (TNF alpha) release. In certain embodiments, the invention provides an anti-HLA-G antibody for
25 use in a method of immunomodulation to directly or indirectly induce proliferation, activation e.g. by release of immunostimulatory cytokines like TNFa and IFNg or further recruitment of immune cells in an individual comprising administering to the individual an effective of the anti-HLA-G antibodyimmunomodulation to directly or
30 indirectly induce proliferation, activation e.g. by release of immunostimulatory cytokines like TNFa and IFNg or further recruitment of immune cells.

In further embodiments, the invention provides an anti-HLA-G antibody for use in the inhibition of immunesuppression in tumors (tumor cells). In further embodiments, the invention provides an anti-HLA-G antibody for use in restoration

of HLA-G specific suppressed immune response (e.g. cytokine release by immune cells (e.g. TNF alpha release by monocytes).

An “individual” according to any of the above embodiments is preferably a human. In a further aspect, the invention provides for the use of an anti-HLA-G antibody in the manufacture or preparation of a medicament. In one embodiment, the medicament is for treatment of cancer. In a further embodiment, the medicament is for use in a method of treating cancer comprising administering to an individual having cancer an effective amount of the medicament. In a further embodiment, the medicament is for inducing cell mediated lysis of cancer cells. In a further embodiment, the medicament is for use in a method of inducing cell mediated lysis of cancer cells in an individual suffering from cancer comprising administering to the individual an amount effective of the medicament to induce apoptosis in a cancer cell/ or to inhibit cancer cell proliferation. An “individual” according to any of the above embodiments may be a human.

In a further aspect, the invention provides a method for treating cancer. In one embodiment, the method comprises administering to an individual having cancer an effective amount of an anti-HLA-G. An “individual” according to any of the above embodiments may be a human.

In a further aspect, the invention provides a method for inducing cell mediated lysis of cancer cells in an individual suffering from cancer. In one embodiment, the method comprises administering to the individual an effective amount of an anti-HLA-G to induce cell mediated lysis of cancer cells in the individual suffering from cancer. In one embodiment, an “individual” is a human.

In a further aspect, the invention provides pharmaceutical formulations comprising any of the anti-HLA-G antibodies provided herein, e.g., for use in any of the above therapeutic methods. In one embodiment, a pharmaceutical formulation comprises any of the anti-HLA-G antibodies provided herein and a pharmaceutically acceptable carrier.

An antibody of the invention (and any additional therapeutic agent) can be administered by any suitable means, including parenteral, intrapulmonary, and intranasal, and, if desired for local treatment, intralesional administration. Parenteral infusions include intramuscular, intravenous, intra-arterial, intraperitoneal, or subcutaneous administration. Dosing can be by any suitable route, e.g. by injections, such as intravenous or subcutaneous injections, depending in part on whether the

- 61 -

administration is brief or chronic. Various dosing schedules including but not limited to single or multiple administrations over various time-points, bolus administration, and pulse infusion are contemplated herein.

5 Antibodies of the invention would be formulated, dosed, and administered in a fashion consistent with good medical practice. Factors for consideration in this context include the particular disorder being treated, the particular mammal being treated, the clinical condition of the individual patient, the cause of the disorder, the site of delivery of the agent, the method of administration, the scheduling of administration, and other factors known to medical practitioners. The antibody need
10 not be, but is optionally formulated with one or more agents currently used to prevent or treat the disorder in question. The effective amount of such other agents depends on the amount of antibody present in the formulation, the type of disorder or treatment, and other factors discussed above. These are generally used in the same dosages and with administration routes as described herein, or about from 1 to 99%
15 of the dosages described herein, or in any dosage and by any route that is empirically/clinically determined to be appropriate.

For the prevention or treatment of disease, the appropriate dosage of an antibody of the invention (when used alone or in combination with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the type of
20 antibody, the severity and course of the disease, whether the antibody is administered for preventive or therapeutic purposes, previous therapy, the patient's clinical history and response to the antibody, and the discretion of the attending physician. The antibody is suitably administered to the patient at one time or over a series of treatments. Depending on the type and severity of the disease, about 1 $\mu\text{g}/\text{kg}$ to
25 15 mg/kg (e.g. 0.5mg/kg - 10 mg/kg) of antibody can be an initial candidate dosage for administration to the patient, whether, for example, by one or more separate administrations, or by continuous infusion. One typical daily dosage might range from about 1 $\mu\text{g}/\text{kg}$ to 100 mg/kg or more, depending on the factors mentioned above. For repeated administrations over several days or longer, depending on the
30 condition, the treatment would generally be sustained until a desired suppression of disease symptoms occurs. One exemplary dosage of the antibody would be in the range from about 0.05 mg/kg to about 10 mg/kg. Thus, one or more doses of about 0.5 mg/kg, 2.0 mg/kg, 4.0 mg/kg or 10 mg/kg (or any combination thereof) may be administered to the patient. Such doses may be administered intermittently, e.g.
35 every week or every three weeks (e.g. such that the patient receives from about two to about twenty, or e.g. about six doses of the antibody). An initial higher loading

- 62 -

5 dose, followed by one or more lower doses may be administered. An exemplary dosing regimen comprises administering an initial loading dose of about 4 mg/kg, followed by a weekly maintenance dose of about 2 mg/kg of the antibody. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

It is understood that any of the above formulations or therapeutic methods may be carried out using an immunoconjugate of the invention in place of or in addition to an anti-HLA-G antibody.

10 It is understood that any of the above formulations or therapeutic methods may be carried out using an immunoconjugate of the invention in place of or in addition to an anti-HLA-G antibody.

II. Articles of Manufacture

15 In another aspect of the invention, an article of manufacture containing materials useful for the treatment, prevention and/or diagnosis of the disorders described above is provided. The article of manufacture comprises a container and a label or package insert on or associated with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The containers may be formed from a variety of materials such as glass or plastic. The container holds a composition which is by itself or combined with another composition effective for treating, preventing and/or diagnosing the condition and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle). At least one active agent in the composition is an antibody of the invention. The label or package insert indicates that the composition is used for treating the condition of choice. Moreover, the article of manufacture may comprise (a) a first container with a composition contained therein, wherein the composition comprises an antibody of the invention; and (b) a second container with a composition contained therein, wherein the composition comprises a further cytotoxic or otherwise therapeutic agent. The article of manufacture in this embodiment of the invention may further comprise a package insert indicating that the compositions can be used to treat a particular condition. Alternatively, or additionally, the article of manufacture may further comprise a second (or third) container comprising a pharmaceutically-acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from

20

25

30

a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

The following examples and figures are provided to aid the understanding of the present invention, the true scope of which is set forth in the appended claims. It is understood that modifications can be made in the procedures set forth without departing from the spirit of the invention.

Description of the amino acid sequences

Anti-HLAG antibodies (variable regions and hypervariable regions (HVRs)):

10	SEQ ID NO: 1	heavy chain HVR-H1, HLA-G-0031
	SEQ ID NO: 2	heavy chain HVR-H2, HLA-G-0031
	SEQ ID NO: 3	heavy chain HVR-H3, HLA-G-0031
	SEQ ID NO: 4	light chain HVR-L1, HLA-G-0031
	SEQ ID NO: 5	light chain HVR-L2, HLA-G-0031
15	SEQ ID NO: 6	light chain HVR-L3, HLA-G-0031
	SEQ ID NO: 7	heavy chain variable domain VH, HLA-G-0031
	SEQ ID NO: 8	light chain variable domain VL, HLA-G-0031
	SEQ ID NO: 9	heavy chain HVR-H1, HLA-G-0039
	SEQ ID NO: 10	heavy chain HVR-H2, HLA-G-0039
20	SEQ ID NO: 11	heavy chain HVR-H3, HLA-G-0039
	SEQ ID NO: 12	light chain HVR-L1, HLA-G-0039
	SEQ ID NO: 13	light chain HVR-L2, HLA-G-0039
	SEQ ID NO: 14	light chain HVR-L3, HLA-G-0039
	SEQ ID NO: 15	heavy chain variable domain VH, HLA-G-0039
25	SEQ ID NO: 16	light chain variable domain VL, HLA-G-0039
	SEQ ID NO: 17	heavy chain HVR-H1, HLA-G-0041
	SEQ ID NO: 18	heavy chain HVR-H2, HLA-G-0041
	SEQ ID NO: 19	heavy chain HVR-H3, HLA-G-0041
	SEQ ID NO: 20	light chain HVR-L1, HLA-G-0041
30	SEQ ID NO: 21	light chain HVR-L2, HLA-G-0041
	SEQ ID NO: 22	light chain HVR-L3, HLA-G-0041
	SEQ ID NO: 23	heavy chain variable domain VH, HLA-G-0041
	SEQ ID NO: 24	light chain variable domain VL, HLA-G-0041
	SEQ ID NO: 25	heavy chain HVR-H1, HLA-G-0090
35	SEQ ID NO: 26	heavy chain HVR-H2, HLA-G-0090

- 64 -

	SEQ ID NO: 27	heavy chain HVR-H3, HLA-G-0090
	SEQ ID NO: 28	light chain HVR-L1, HLA-G-0090
	SEQ ID NO: 29	light chain HVR-L2, HLA-G-0090
	SEQ ID NO: 30	light chain HVR-L3, HLA-G-0090
5	SEQ ID NO: 31	heavy chain variable domain VH, HLA-G-0090
	SEQ ID NO: 32	light chain variable domain VL, HLA-G-0090
	SEQ ID NO: 33	humanized variant heavy chain variable domain VH, HLA-G-0031-0104 (HLA-G-0104)
	SEQ ID NO: 34	humanized variant light chain variable domain VL, HLA-G-0031-0104 (HLA-G-0104)
10		
	Further sequences	
	SEQ ID NO: 35:	exemplary human HLA-G
	SEQ ID NO: 36:	exemplary human HLA-G extracellular domain (ECD)
	SEQ ID NO: 37:	exemplary human β 2M
15	SEQ ID NO: 38:	modified human HLA-G (wherein the HLA-G specific amino acids have been replaced by HLA-A consensus amino acids (= degrafted HLA-G see also Figure 1) ECD)
	SEQ ID NO: 39:	exemplary human HLA-A2
	SEQ ID NO: 40:	exemplary human HLA-A2 ECD
20	SEQ ID NO: 41:	exemplary mouse H2Kd ECD
	SEQ ID NO: 42:	exemplary rat RT1A ECD
	SEQ ID NO: 43:	exemplary human HLA-G β 2M MHC class I complex
	SEQ ID NO: 44:	exemplary modified human HLA-G β 2M MHC class I complex (wherein the HLA-G specific amino acids have been replaced by HLA-A consensus amino acids (= degrafted HLA-G) see also Figure 1)
25		
	SEQ ID NO: 45:	exemplary mouse H2Kd β 2M MHC class I complex
	SEQ ID NO: 46:	exemplary human HLA-G/ mouse H2Kd β 2M MHC class I complex wherein the positions specific for human HLA-G are grafted onto the mouse H2Kd framework
30		
	SEQ ID NO: 47:	exemplary rat RT1A β 2M MHC class I complex
	SEQ ID NO: 48:	exemplary human HLA-G/ rat RT1A β 2M MHC class I complex wherein the positions specific for human HLA-G are grafted onto the rat RT1A framework
35		
	SEQ ID NO: 49	linker and his-Tag
	SEQ ID NO: 50	peptide
	SEQ ID NO: 51	human kappa light chain constant region

- 65 -

- SEQ ID NO: 52 human lambda light chain constant region
 SEQ ID NO: 53 human heavy chain constant region derived from IgG1
 SEQ ID NO: 54 human heavy chain constant region derived from IgG1 with
 mutations L234A, L235A and P329G
 5 SEQ ID NO: 55 human heavy chain constant region derived from IgG4

The amino acid sequences of the anti-HLAG antibodies (variable regions with underlined and bold hypervariable regions (HVRs)) ::

10 SEQ ID NO: 7: heavy chain variable domain VH, HLA-G-0031:

QVKLMQSGAALVKPGTSVKMSCNASGYTFT**DYWVSWVKQSHGKRLEWV**
GEISPNSGASNFDENFKDKATLTVDKSTSTAYMELSRLTSEDSAIYYCTRS
SHGSFRWFAYWGQGLTVTVSS

15

SEQ ID NO: 8: light chain variable domain VL, HLA-G-0031:

AIVLNQSPSSIVASQGEKVTITC**CRASSVSSNHLHWYQQKPGAFP**KFVIY**ST**
SQRASGIPSRFSGSGSGTSYSFTISRVEADVATYYC**QOGSSNPYTFGAGTK**
 20 LELK

20

SEQ ID NO: 33:humanized variant heavy chain variable domain VH, HLA-G-0031-
 0104 (HLA-G-0104):

25 QVQLVQSGAEVKKPGASVKVSCKASGYTFT**DYWVSWVRQAPGQRLEWM**
GEISPNSGASNFDENFQGRVTITRDTSASTAYMELSSLRSEDTAVYYCTRS
SHGSFRWFAYWGQGLTVTVSS

25

SEQ ID NO: 34:humanized variant light chain variable domain VL, HLA-G-0031-
 0104 (HLA-G-0104):

30 DIQMTQSPSSLSASVGDRVTITC**CRASSVSSNHLHWYQQKPGKAPKFLIYS**
TSQRASGVPSRFSGSGSGTEFTLTISSLQPEDFATYYC**QOGSSNPYTFGQGT**
 KLEIK

30

SEQ ID NO: 15: heavy chain variable domain VH, HLA-G-0039:

EVQLLESGGGLVQPGGSLRLSCAASGFTF**SSYAMNWVRQAPGKGLEWVS**
VISGSGVSTYYADSVKGRFTISRDNSRNTLSLQMNSLRAEDTAVYYCA**KD**
 35 **GSYNYGYGDYFDYWGQGLTVTVSS**

35

SEQ ID NO: 16: light chain variable domain VL, HLA-G-0039

- 66 -

DIVMTQSPDSLAVSLGERATINCKKSSQSVLYSSKNKNYLAWYQQKPGQPP
 KLLIYWASTRESGVDPDRFSGSGSGTDFTLTISLQAEDVAVYYCQQYYNTP
RTFGQGTKVEIK

SEQ ID NO: 23: heavy chain variable domain VH, HLA-G-0041:

5 EVQLLES GGGLVQPGGSLRLSCAASGFTFSTYGMSWVRQAPGKGLEWVS
VISGGGVSTYYADSVKGRRFTISRDN SKNTLYLQMNRLRAEDTAVYYCAK
DGSYNYGYGDYFDYWGQGLVTVSS

SEQ ID NO: 24: light chain variable domain VL, HLA-G-0041

10 DIVMTQSPDSLAVSLGERATINCKKSSQNVLYSSNNKNYLAWYQQKPGQPP
 KLLIYWASTRESGVDPDRFSGSGSGTDFTLTISLQAEDVAVYYCQQYYNTP
RTFGQGTKVEIK

SEQ ID NO: 31: heavy chain variable domain VH, HLA-G-0090:

15 QVQLQQSGPGLLKPSQTLSTLCAISGDSVSNRAAWNWIRQSPSRGLEWLG
RTYYRSKWYNDYAVSVQGRITLIPDTSKNQFSLRLNSVTPEDTAVYYCAS
VRAVAPFDYWGQGVVTVSS

SEQ ID NO: 32: light chain variable domain VL, HLA-G-0090

20 DIVMTQSPDSLAVSLGERATINCKKSSQSVLNSSNNKNNLAWYQQQPGQPP
 KLLIYWASTRESGVDPDRFSGSGSGTDFTLTISLQAEDVAVYFCQQYYRTP
WTFGQGTKVEIK

In the following specific embodiments of the invention are listed:

1. An isolated antibody that specifically binds to human HLA- wherein the antibody comprises
 - 25 A) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:3; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid

- 67 -

sequence of SEQ ID NO:5 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6; or

- 5 B) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:10, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:11; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:13 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14; or
- 10 C) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:18, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:19; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:20; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:21 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:22; or
- 15 D) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:26, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:27; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:28; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:29 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.
- 20
2. The antibody according to embodiment 1, wherein the antibody comprises
- 25 A)
- i) comprises a VH sequence of SEQ ID NO:7 and a VL sequence of SEQ ID NO:8;
- ii) or humanized variant of the VH and VL of the antibody under i); or
- iii) comprises a VH sequence of SEQ ID NO:33 and a VL sequence of SEQ ID NO:34; or
- 30

- 68 -

B)

comprises a VH sequence of SEQ ID NO:15 and a VL sequence of SEQ ID NO:16; or

C)

5 comprises a VH sequence of SEQ ID NO:23 and a VL sequence of SEQ ID NO:24; or

D)

comprises a VH sequence of SEQ ID NO:31 and a VL sequence of SEQ ID NO:32.

- 10 3. An isolated antibody that binds to human HLA-G, wherein the antibody
- a) binds to the same epitope as an antibody which comprises a VH sequence of SEQ ID NO:7 and a VL sequence of SEQ ID NO:8;
 - or b) binds to the same epitope as an antibody which comprises a VH sequence of SEQ ID NO:31 and a VL sequence of SEQ ID NO:32.
- 15 4. The anti-HLA-G antibody according to any one of embodiments 1 to 4, wherein the antibody
- a) does not crossreact with a modified human HLA-G β 2M MHC I complex comprising SEQ ID NO:44; and/ or
 - 20 b) does not crossreact with human HLA-A2 β 2M MHC I complex comprising SEQ ID NO:39 and SEQ ID NO: 37; and/ or
 - c) does not crossreact with a mouse H2Kd β 2M MHC I complex comprising SEQ ID NO:45; and/ or
 - e) does not crossreact with rat RT1A β 2M MHC I complex comprising SEQ ID NO:47; and/ or
 - 25 f) inhibits ILT2 binding to monomeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43); and/or

- 69 -

- g) inhibits ILT2 binding to trimeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43), by more than 50% (in one embodiment by more than 60 %) (when compared to the binding without antibody) (see Example 4b); and/or
- 5 h) inhibits ILT2 binding to monomeric and/or dimeric and/or trimeric HLA-G β 2M MHC I complex (comprising SEQ ID NO: 43), by more than 50% (in one embodiment by more than 80 %) (when compared to the binding without antibody) (see Example 4b); and/or
- 10 i) inhibits ILT2 binding to (HLA-G on) JEG3 cells (ATCC No. HTB36) (by more than 50 % (in one embodiment by more than 80%)) (when compared to the binding without antibody) (see Example 6); and/or
- 15 j) binds to (HLA-G on) JEG3 cells (ATCC No. HTB36) (see Example 5), and inhibits ILT2 binding to (HLA-G on) JEG3 cells (ATCC No. HTB36) (by more than 50 % (in one embodiment by more than 80%)) (when compared to the binding without antibody) (see Example 6); and/or
- k) inhibits CD8a binding to HLAG by more than 80% (when compared to the binding without antibody) (see e.g Example 4c); and/or
- 20 l) restores HLA-G specific suppressed immune response (e.g.. suppressed Tumor necrose factor (TNF) alpha release) by monocytes co-cultured with JEG-3 cells (ATCC HTB36).
5. The antibody according to any one of the preceding embodiments, wherein the antibody is of IgG1 isotype.
- 25 6. The antibody according embodiment 5, wherein the antibody is of IgG1 isotype with mutations L234A, L235A and P329G (numbering according to the EU index of Kabat).
7. Isolated nucleic acid encoding the antibody according to any one of the preceding embodiments.
8. A host cell comprising the nucleic acid of embodiment 7.

- 70 -

9. A method of producing an antibody comprising culturing the host cell of embodiment 7 so that the antibody is produced.
10. The method of embodiment 9, further comprising recovering the antibody from the host cell.
- 5 11. A pharmaceutical formulation comprising the antibody according any one of embodiments 1 to 6 and a pharmaceutically acceptable carrier.
12. The antibody according any one of embodiments 1 to 6 for use as a medicament.
- 10 13. The antibody according any one of embodiments 1 to 6 for use in treating cancer.
14. Use of the antibody according any one of embodiments 1 to 6 in the manufacture of a medicament.
15. The use of embodiment 14, wherein the medicament is for treatment of cancer.
- 15 16. A method of treating an individual having cancer comprising administering to the individual an effective amount of the antibody of embodiments 1 to 6.
17. A method for selecting anti-HLAG antibodies (e.g. according to embodiments 1 to 6) comprising the following steps:
 - 20 a) determining the binding of anti-HLAG antibodies to human HLA-G β 2M MHC I complex comprising SEQ ID NO: 43 by a Surface Plasmon Resonance assay;
 - b) determining the inhibition of ILT2 binding to monomeric and/or dimeric and/or trimeric HLA-G β 2M MHC I complex by the respective anti-HLAG antibodies; and
 - 25 c) selecting anti-HLAG antibodies which inhibit ILT2 binding to monomeric HLA-G β 2M MHC I complex by more than 50% (in one embodiment by more than 80%) (when compared to the binding without antibody), or selecting anti-HLAG antibodies which inhibit ILT2 binding to monomeric and/or dimeric and/or trimeric HLA-G β 2M MHC I complex by more than 50% (in one embodiment by more than 70%) (when compared to the
30 binding without antibody).

- 71 -

- d) restores HLA-G specific suppressed immune response (e.g.. suppressed Tumor necrose factor (TNF) alpha release) by monocytes co-cultured with JEG-3 cells (ATCC HTB36).
18. A method for selecting anti-HLAG antibodies (e.g. according to embodiment 6) comprising the following steps:
- 5
- a) determining the binding of anti-HLAG antibodies to JEG3 cells ((ATCC No. HTB36) in a flow cytometry assay (using Fluorescence-activated cell sorting) (FACS assay).
- b) determining the inhibition of ILT2 binding to JEG3 cells ((ATCC No. HTB36) by the respective anti-HLAG antibodies a flow cytometry assay (using Fluorescence-activated cell sorting) (FACS assay); and
- 10
- c) selecting anti-HLAG antibodies which bind to JEG3 (ATCC No. HTB36) cells, and which inhibit ILT2 binding to JEG3 cells (ATCC No. HTB36) by more than 50 % (in one embodiment by more than 80%) when compared to the binding without antibody.
- 15

Examples

Recombinant DNA techniques

Standard methods were used to manipulate DNA as described in Sambrook, J. et al.,
20 Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. The molecular biological reagents were used according to the manufacturer's instructions.

Gene and oligonucleotide synthesis

Desired gene segments were prepared by chemical synthesis at Geneart GmbH
25 (Regensburg, Germany). The synthesized gene fragments were cloned into an E. coli plasmid for propagation/amplification. The DNA sequences of subcloned gene fragments were verified by DNA sequencing. Alternatively, short synthetic DNA fragments were assembled by annealing chemically synthesized oligonucleotides or via PCR. The respective oligonucleotides were prepared by metabion GmbH
30 (Planegg-Martinsried, Germany).,

Description of the basic/standard mammalian expression plasmid

For the expression of a desired gene/protein (e.g. full length antibody heavy chain, full length antibody light chain, or an MHC class I molecule, e.g. HLA-G, or an MHC class I molecule fused to peptide and beta-2 microglobulin, e.g. HLA-G fused to HLA-G binding peptide and or beta-2 microglobulin) a transcription unit comprising the following functional elements is used:

- the immediate early enhancer and promoter from the human cytomegalovirus (P-CMV) including intron A,
- a human heavy chain immunoglobulin 5'-untranslated region (5'UTR),
- 10 - a murine immunoglobulin heavy chain signal sequence,
- a gene/protein to be expressed (e.g. full length antibody heavy chain or MHC class I molecule), and
- the bovine growth hormone polyadenylation sequence (BGH pA).

Beside the expression unit/cassette including the desired gene to be expressed the basic/standard mammalian expression plasmid contains

- an origin of replication from the vector pUC18 which allows replication of this plasmid in E. coli, and
- a beta-lactamase gene which confers ampicillin resistance in E. coli.

Protein determination

20 The protein concentration of purified polypeptides was determined by determining the optical density (OD) at 280 nm, using the molar extinction coefficient calculated on the basis of the amino acid sequence of the polypeptide.

Example 1**Generation of HLA-G chimeric molecules for screening and counterscreening**

25 Due to high homology (>98%) with other MHC I molecules, immunisation with HLA-G molecules results in generation of polyclonal sera, composed of a mixture of MHC-I crossreactive antibodies as well as truly HLA-G specific antibodies.

30 So far no tools have been provided to select truly HLA-G specific antibodies without crossreactivity to other human MHC-I (e.g. HLA-A), and to further select those with receptor blocking function.

- 73 -

We identified unique HLA-G positions in combination to positions necessary for structural conformity and receptor interaction (ILT2/4 and KIR2DL4.)

Unique and proximal positions of human HLA-G were then „grafted“ on MHC class I complex molecules from different rodent species (such as rat RT1A and mouse H2kd) to generate „*chimeric*“ immunogen/screening antigens.

Antibodies generated were subjected to stringent screening for binding/specificity, (and no binding/specificity to counterantigens, respectively).

Screening antigens:

- 10 – rec. HLA-G expressed as human HLA-G β 2M MHC complex comprising SEQ ID NO: 43
- 15 – HLA-G specific sequences grafted onto rat RT-1 and mouse H2kd (SEQ ID NO: 46: human HLA-G/ mouse H2Kd β 2M MHC class I complex wherein the positions specific for human HLA-G are grafted onto the mouse H2Kd framework and SEQ ID NO: 48: human HLA-G/ rat RT1A β 2M MHC class I complex wherein the positions specific for human HLA-G are grafted onto the rat RT1A framework)
- Natural HLA-G MHC class I complex expressing cells (e.g. Jeg3 cells), or human HLA-G transfected cell lines SKOV3 HLA-G+ and PA-TU-8902 HLA-G+

20 Screening counter antigens:

- 25 – Counter antigens (MHC class I complexes) with other HLA-A sequences (HLA-A2 and HLA-G^{degrafted with HLA-A consensus sequence}) combined with different peptides) (see e.g. SEQ ID NO 40 (HLA-A2) and SEQ ID NO: 44 HLA-A consensus sequence on HLA-G framework)
- Counter antigens (MHC class I complexes) from other species such as rat RT-1 and mouse H2kd (SEQ ID NO: 45 and SEQ ID NO: 47)
- Unmodified tumor cell lines SKOV3 and PA-TU-8902, which are characterized by absence of HLA-G expression.

Design of chimeric HLA-G antigens for use in immunization and screening for the generation of HLA-specific antibodies (see Figure 1):

5 Design of a chimeric rat MHC I molecule (RT1-A) carrying HLA-G unique positions (SEQ ID NO: 48) for use in immunization of wildtype (wt) and transgenic rats, or rabbits and mice etc., and/or for use screening assays:

10 HLA-G unique positions were identified by the alignment of 2579 HLA-A, 3283 HLA-B, 2133 HLA-C, 15 HLA-E, 22 HLA-F, and 50 HLA-G sequences from IMGT (as available on 6. Feb 2014). Those residues of HLA-G that occur in less than 1% (mostly ~0%) of the sequences of any of the 3 sequence sets HLA-A, HLA-B, and a combined set of HLA-C + HLA-E + HLA-F are called HLA-G unique positions.

The 4 core HLA-G unique positions (2 in alpha-1 and 2 in alpha-3) show no polymorphism in the set of HLA-G sequences and none of the other HLA genes contain the HLA-G specific residues at these positions (except 1x HLA-A for M100, 1x HLA-B for Q103, and 1x HLA-C for Q103).

15 The crystal structure of rat RT1-A (Rudolph, M.G. et al. J.Mol.Biol. 324: 975-990 (2002); PDB code: 1KJM) was superimposed on the crystal structure of human HLA-G (Clements, C.S. et al. PROC.NATL.ACAD.SCI.USA 102: 3360-3365 (2005); PDB code: 1YDP). The overall structure of the alpha-chain and the associated beta-2-microglobulin is conserved.

20 HLA-G unique positions were identified in the RT1-A structure by comparison of the sequence and structural alignments. In a first step, unique HLA-G positions were identified that are exposed on the molecular surface of HLA-G and RT1-A and thus accessible for an antibody. Unique positions that are buried within the protein fold were excluded for engineering. In a second step, structurally proximal residues were identified, that also need to be exchanged to make the corresponding region „HLA-G-like“, i.e. to generate real HLA-G epitopes containing the unique positions rather than generating HLA-G/rat RT1-A chimeric epitopes that would be artificial. All the positions that were thus selected for mutation were analyzed for structural fit of the respective residue from HLA-G to avoid possible local disturbances of the molecular structure upon mutation.

25

30

A chimeric mouse MHC I molecule (H2Kd) carrying HLA-G unique positions (SEQ ID NO: 46) for use in immunization and/or for use screening assays was generated analogously.

Design of HLA-A based counter antigens by “de-grafting” of HLA-G unique positions towards a HLA-A consensus sequence for use as a counter-antigen in screening (SEQ ID NO:44)

5 Unique positions derived from the multiple sequence alignment were analyzed in a crystal structure of human HLA-G (PDB code: 1YDP). First, positions that are not exposed on the HLA-G surface and are thus not accessible for an antibody were excluded for engineering. Second, the surface exposed residues were analyzed for feasibility of amino acid exchange (i.e. exclusion of possible local disturbances of the molecular structure upon mutation of the relevant position). In total, 14 positions
10 were validated for exchange. The amino acids in the validated positions were mutated towards a HLA-A consensus sequence derived from a multiple sequence alignment of 2579 HLA-A sequences downloaded from IMGT (as available on 6. Feb 2014).

15 **Generation of expression plasmids for soluble classical and non-classical MHC class I molecules**

The recombinant MHC class I genes encode N-terminally extended fusion molecules consisting of a peptide known to be bound by the respective MHC class I molecule, beta-2 microglobulin, and the respective MHC class I molecule.

20 The expression plasmids for the transient expression of soluble MHC class I molecules comprised besides the soluble MHC class I molecule expression cassette an origin of replication from the vector pUC18, which allows replication of this plasmid in *E. coli*, and a beta-lactamase gene which confers ampicillin resistance in *E. coli*.

25 The transcription unit of the soluble MHC class I molecule comprised the following functional elements:

- the immediate early enhancer and promoter from the human cytomegalovirus (P-CMV) including intron A,
- a human heavy chain immunoglobulin 5'-untranslated region (5'UTR),
- a murine immunoglobulin heavy chain signal sequence,
- 30 - an N-terminally truncated *S. aureus* sortase A encoding nucleic acid, and
- the bovine growth hormone polyadenylation sequence (BGH pA).

The amino acid sequences of the mature soluble MHC class I molecules derived from the various species are:

- 76 -

- SEQ ID NO: 43: exemplary human HLA-G β 2M MHC class I complex
- SEQ ID NO: 44: exemplary modified human HLA-G β 2M MHC class I complex (wherein the HLA-G specific amino acids have been replaced by HLA consensus amino acids (= degrafted HLA-G see also Figure 1)
- 5 SEQ ID NO: 45: exemplary mouse H2Kd β 2M MHC class I complex
- SEQ ID NO: 46: exemplary human HLA-G/ mouse H2Kd β 2M MHC complex wherein the positions specific for human HLA-G are grafted onto the mouse H2Kd framework
- SEQ ID NO: 47: exemplary rat RT1A β 2M MHC class I complex
- 10 SEQ ID NO: 48: exemplary human HLA-G/ rat RT1A β 2M MHC complex wherein the positions specific for human HLA-G are grafted onto the rat RT1A framework

15 For the exemplary HLA-A2 β 2M MHC class I complex used in screening the following components were used and the complex was expressed in E.Coli and purified.

MHCI complex HLA-A2 / β 2M (SEQ ID NOs 40 and 37) (both with an additional N-terminal methionine) + VLDFAPPGA peptide (SEQ ID NO: 50) + linker and his-Tag (SEQ ID NO: 49)

20 **Example 2**

Immunization campaigns

A) immunization of mice and rats

a. Chimeric proteins (for tolerance against unspecific MHC-I/HLA and direction to unique HLA-G positions)

25 Balb/C mice obtained from Charles River Laboratories International, Inc. were used for immunization. The animals were housed according to the Appendix A "Guidelines for accommodation and care of animals" in an AAALACi accredited animal facility. All animal immunization protocols and experiments were approved by the Government of Upper Bavaria (permit number 55.2-1-54-2531-19-10 and

30 55.2-1-54-2532-51-11) and performed according to the German Animal Welfare Act and the Directive 2010/63 of the European Parliament and Council.

Balb/C mice (n=5), 6-8 week old, received five rounds of immunization with a chimeric H2Kd/HLA-G molecule (SEQ ID NO: 46 ("HLA-G-0006")) over a course

- 77 -

of 4 weeks. Before each immunization, mice were anesthetized with a gas mixture of oxygen and isoflurane. For the first immunization, 15 µg protein dissolved in 20 mM His/HisCl, 140 mM NaCl, pH 6.0, were mixed with an equal volume of CFA (BD Difco, #263810) and administered subcutaneously (s.c.) to six sites proximal to draining lymph nodes, along the back of the mice, with two sites at the nape of the neck and two sites bilaterally to the groin and calf. Another 15 µg of protein emulsified in RIBI adjuvant (Sigma-Aldrich, #S6322) was administered to six juxtaposed sites along the abdomen, with two sites each bilaterally to the axilla, groin, and thigh. Descending antigen doses of booster immunizations were given on days 7 (10 µg), 14 (5 µg), 21 (5 µg), and 28 (5 µg) in a similar fashion except RIBI adjuvant was used throughout, and only along the abdomen. Three days after the final immunization, mice were euthanized and the bilateral popliteal, superficial inguinal, axillary, and branchial lymph nodes were isolated aseptically and prepared for hybridoma generation. Serum was tested for recombinant human HLA-G and immunogen-specific total IgG antibody production by ELISA after the third and fifth immunization.

Another set of Balb/C mice (n=5), 6-8 week old, received three immunizations with the chimeric H2Kd/HLA-G molecule (HLA-G-0006) over a course of 3 months. For the first immunization, 100 µg protein dissolved in 20 mM His/HisCl, 140 mM NaCl, pH 6.0, were mixed with an equal volume of CFA (BD Difco, #263810) and administered intraperitoneally (i.p.). Booster immunizations were given on days 28 and 56 in a similar fashion, except that incompletes Freund's adjuvant (IFA from BD Difco, #DIFC263910) was used. Four to five weeks after the final immunization, mice received approximately 25µg of the immunogen intravenously (i.v.) in sterile PBS and 72h later, spleens were aseptically harvested and prepared for hybridoma generation. Serum was tested for recombinant human HLA-G (SEQ ID NO: 43 ("HLA-G-0003")), and immunogen-specific chimeric H2Kd/HLA-G molecule (SEQ ID NO: 46 ("HLA-G-0006")) and counterscreened with "degrafted" human HLA-G with consensus HLA-A specific positions (SEQ ID NO: 44 ("HLA-G-0007")) and murine H2kd protein (SEQ ID NO: 45 "HLA-G-0009")) total IgG antibody production by ELISA after the third immunization.

b. wt HLA-G protein

CD rats obtained from Charles River Laboratories International, Inc. were used for immunization. The animals were housed according to the Appendix A "Guidelines for accommodation and care of animals" in an AAALACi accredited animal facility.

All animal immunization protocols and experiments were approved by the Government of Upper Bavaria (permit number 55.2-1-54-2532-51-11) and performed according to the German Animal Welfare Act and the Directive 2010/63 of the European Parliament and Council.

5 CD rats (n=4), 6-8 week old, received four immunizations with recombinant human HLA-G protein (SEQ ID NO: 43 (“HLA-G-0003”)) over a course of 4 months. For the first immunization, 100 µg protein dissolved in 20 mM His/HisCl, 140 mM NaCl, pH 6.0, were mixed with an equal volume of CFA (BD Difco, #263810) and administered intraperitoneally. Booster immunizations were given on days 28, 56
10 and 84 in a similar fashion, except that incompletes Freund’s adjuvant (IFA from BD Difco, #DIFC263910) was used throughout. Three to four weeks after the final immunization, rats received approximately 75µg of the immunogen i.v. in sterile PBS; and 72h later, spleens were aseptically harvested and prepared for hybridoma generation. Serum was tested for recombinant HLA-G (SEQ ID NO: 43 (“HLA-G-0003”)) -specific IgG1, IgG1a, IgG2b and IgG2c antibody production by ELISA
15 after the third and fourth immunization and counterscreened with “degrafted” human HLA-G with consensus HLA-A specific positions (SEQ ID NO: 44 (“HLA-G-0007”)).

c. JEG3 cells (ATCC No. HTB36) (naturally expressing HLA-G)

20 CD rats obtained from Charles River Laboratories International, Inc. were used for immunization. The animals were housed according to the Appendix A “Guidelines for accommodation and care of animals” in an AAALACi accredited animal facility. All animal immunization protocols and experiments were approved by the Government of Upper Bavaria (permit number AZ. 55.2-1-54- 2531-83-13) and
25 performed according to the German Animal Welfare Act and the Directive 2010/63 of the European Parliament and Council.

Two groups of CD rats (n=2), 6-8 week old, received either five (group A) or seven (group B) immunizations using JEG-3 cells (ATCC HTB36) over a course of five (A) to seven (B) months, respectively. For the first immunization, 1×10^7 cells dissolved in sterile PBS, were mixed with an equal volume of CFA (BD Difco, #263810) and administered intraperitoneally. Booster immunizations were given to
30 A and B on days 28, 56, 84, 112, 140 (B only) and 168 (B only) in a similar fashion, except that incompletes Freund’s adjuvant (IFA from BD Difco, #DIFC263910) was used throughout. Three weeks after the final immunization, rats received 100µg of

- 79 -

recombinant human HLA-G protein (SEQ ID NO: 43 (“HLA-G-0003”)) i.v. in sterile PBS; and 72h later, spleens were aseptically harvested and prepared for hybridoma generation. Serum was tested for recombinant HLA-G (SEQ ID NO: 43 (“HLA-G-0003”)) -specific IgG1, IgG1a, IgG2b and IgG2c antibody production
5 -specific IgG1, IgG2a, IgG2b and IgG2c antibody production by ELISA after the third, fifth and seventh immunization, respectively and counterscreened with “degrafted” human HLA-G with consensus HLA-A specific positions (SEQ ID NO: 44 (“HLA-G-0007”)).

d. JEG3/DNA IMS (for boosting effect)

10 CD rats obtained from Charles River Laboratories International, Inc. were used for immunization. The animals were housed according to the Appendix A “Guidelines for accommodation and care of animals” in an AAALACi accredited animal facility. All animal immunization protocols and experiments were approved by the Government of Upper Bavaria (permit number AZ. 55.2-1-54- 2531-83-13) and
15 performed according to the German Animal Welfare Act and the Directive 2010/63 of the European Parliament and Council.

CD rats (n=5), 6-8 week old, received plasmid DNA and cell-based immunizations in an alternating regime over a course of three months. The plasmid DNA HLA-G-0030 (p17747) encoding for human HLA-G as a single chain molecule as well as the
20 naturally HLA-G expressing JEG-3 cells (ATCC HTB36) were used for this purpose, respectively.

For the first immunization, animals were isoflurane-anesthetized and intradermally (i.d.) immunized with 100µg plasmid DNA in sterile H₂O applied to one spot at the shaved back, proximal to the animal’s tail. After i.d. application, the spot was
25 electroporated using following parameters on an ECM 830 electroporation system (BTX Harvard Apparatus): two times 1000V/cm for 0.1ms each, separated by an interval of 125ms, followed by four times 287.5V/cm for 10ms, separated also by intervals of 125ms. For the second immunization on day 14, animals received 1×10^7 cells dissolved in sterile PBS, that were mixed with an equal volume of CFA (BD Difco, #263810) and, after generation of a stable emulsion, administered
30 intraperitoneally. Booster immunizations were given on days 28 (DNA), 42 (cells), 56 (DNA), 70 (cells) in a similar fashion, except that incompletes Freund’s adjuvant (IFA from BD Difco, #DIFC263910) was used for cell immunizations throughout. Four weeks after the final immunization, rats received 100µg of soluble recombinant

- 80 -

human HLA-G MHC class I protein (SEQ ID NO: 43 (“HLA-G-0003”)) i.v. in sterile PBS; and 72h later, spleens were aseptically harvested and prepared for hybridoma generation. Serum was tested for soluble recombinant human HLA-G MHC class I protein (SEQ ID NO: 43 (“HLA-G-0003”))-specific IgG1, IgG2a, IgG2b and IgG2c antibody production by ELISA after the third, fifth and sixth immunization, respectively and counterscreened with “degrafted” human HLA-G with consensus HLA-A specific positions (SEQ ID NO: 44 (“HLA-G-0007”)).

In all immunization strategies a highly polyreactive humoral immune response was induced, recognizing HLA-G, as well as proteins used for counterscreening (e.g. recombinant “degrafted” human HLA-G, chimeric H2Kd/HLA-G molecule or related human HLA-A2 molecules) as analyzed in an ELISA format using polyclonal sera from immunized animals (no data shown).

B) immunization of humanized OMNIRAT line 7 rats

OmniRat Line 7 rats were partnered from Open Monoclonal Technology, Inc. (2747 Ross Road, Palo Alto, CA 94303, USA) and were bred and obtained from Charles River Laboratories International, Inc. The animals were housed according to the Appendix A “Guidelines for accommodation and care of animals” in an AAALACi accredited animal facility. All animal immunization protocols and experiments were approved by the Government of Upper Bavaria (permit number 55.2-1-54-2532-51-11 and 55.2-1-54-2531-83-13) and performed according to the German Animal Welfare Act and the Directive 2010/63 of the European Parliament and Council.

OmniRat Line 7 rats (n=4), 6-8 week old, received four immunizations with recombinant chimeric HLA-G protein (SEQ ID NO: 48 (“HLA-G-0011”)) over a course of 4 months. For the first immunization, 100 µg protein dissolved in 20 mM His/HisCl, 140 mM NaCl, pH 6.0, were mixed with an equal volume of CFA (BD Difco, #263810) and administered intraperitoneally. Booster immunizations were given on days 28, 56 and 84 in a similar fashion, except that incompletes Freund’s adjuvant (IFA from BD Difco, #DIFC263910) was used throughout. Three to four weeks after the final immunization, rats received approximately 50µg of the immunogen i.v. and 25 µg of the immunogen i.p. in sterile PBS and 72hrs later, spleens were aseptically harvested and prepared for hybridoma generation. Serum was tested for recombinant HLA-G (SEQ ID NO: 48 (“HLA-G-0011”))-specific IgG1, IgG2a, IgG2b and IgG2c antibody production by ELISA after the third and

fourth immunization and counterscreened with “degrafted” human HLA-G with consensus HLA-A specific positions (SEQ ID NO: 44 (“HLA-G-0007”)).

5 Alternatively, OmniRat Line 7 rats (n=5), 6-8 week old, received plasmid DNA and cell-based immunizations in an alternating regime over a course of three months. The plasmid DNA encoding for human HLA-G as a single chain molecule (human HLA-G MHC class I protein (SEQ ID NO: 43 (“HLA-G-0003”)) as well as the naturally HLA-G expressing JEG-3 cells (ATCC HTB36) were used for this purpose, respectively.

10 For the first immunization, animals were isoflurane-anesthetized and intradermally (i.d.) immunized with 100µg plasmid DNA in sterile H₂O applied to one spot at the shaved back, proximal to the animal’s tail. After i.d. application, the spot was electroporated using following parameters on an ECM 830 electroporation system (BTX Harvard Apparatus): two times 1000V/cm for 0.1ms each, separated by an interval of 125ms, followed by four times 287.5V/cm for 10ms, separated also by intervals of 125ms. For the second immunization on day 14, animals received 1x10⁷ cells dissolved in sterile PBS, that were mixed with an equal volume of CFA (BD Difco, #263810) and, after generation of a stable emulsion, administered intraperitoneally. Booster immunizations were given on days 28 (DNA), 42 (cells), 56 (DNA), 70 (cells) in a similar fashion, except that incompletes Freund’s adjuvant (IFA from BD Difco, #DIFC263910) was used for cell immunizations throughout. Four weeks after the final immunization, rats received 100µg of soluble recombinant human HLA-G MHC class I protein (SEQ ID NO: 43 (“HLA-G-0003”)) i.v. in sterile PBS; and 72h later, spleens were aseptically harvested and prepared for hybridoma generation. Serum was tested for soluble recombinant human HLA-G MHC class I protein (SEQ ID NO: 43 (“HLA-G-0003”))-specific IgG1, IgG2a, IgG2b and IgG2c antibody production by ELISA after the third, fifth and sixth immunization, respectively and counterscreened with “degrafted” human HLA-G with consensus HLA-A specific positions (SEQ ID NO: 44 (“HLA-G-0007”)).

30 In all immunization strategies a highly polyreactive humoral immune response was induced, recognizing HLA-G, as well as proteins used for counterscreening (e.g. recombinant “degrafted” human HLA-G, chimeric H2Kd/HLA-G molecule or related human HLA-A2 molecules) as analyzed in an ELISA format using polyclonal sera from immunized animals (no data shown).

Obtained antibodies

Using above methods the following antibodies which specifically bind to human anti-HLA-G were obtained: rat HLA-G 0031 from CD rats, human HLAG 0039, HLA-G 0041 and HLA-G 0090 from humanized rats.

5 Binding properties of the obtained anti-HLA-G specific antibodies and biological activities were determined as described in the following Examples and compared to known reference antibodies. Antibody HLA-G-0031 was humanized using its HVRs and VH acceptor human framework of HUMAN_IGHV1-3 and VL acceptor human frameworks HUMAN_IGKV1-17 (V-domain, with one additional back-mutation at position R46F, Kabat numbering).

10 For the identification of a suitable human acceptor framework during the humanization of the HLAG binder HLAG-0031 a combination of two methodologies was used. On the one hand a classical approach was taken by searching for an acceptor framework with high sequence homology to the parental antibody and subsequent *in silico* grafting of the CDR regions onto this acceptor framework. Each amino acid difference of the identified frameworks to the parental antibody was
15 judged for impact on the structural integrity of the binder and backmutations towards the parental sequence were considered whenever appropriate.

On the other hand, an *in silico* tool described in WO 2016/062734 was used to predict the orientation of the VH and VL domains of the humanized versions towards each other. This was carried out for the virtual grafts of the CDRs on all possible human
20 germline combinations. The results were compared to the VH VL domain orientation of the parental binder to select for framework combinations which are close in geometry to the starting antibody.

25 **Anti-HLAG antibody antibodies (SEQ ID Nos of variable regions and hypervariable regions (HVRs)):**

Anti-HLAG antibody	HVR-H1	HVR-H2	HVR-H3	HVR-L1	HVR-L2	HVR-L3	VH	VL
HLA-G-0031	SEQ ID NO: 1	SEQ ID NO: 2	SEQ ID NO: 3	SEQ ID NO: 4	SEQ ID NO: 5	SEQ ID NO: 6	SEQ ID NO: 7	SEQ ID NO: 8

HLA-G-0031-0104 (humanized variant of HLA-G-0031) (HLA-G-0104)	SEQ ID NO: 1	SEQ ID NO: 2	SEQ ID NO: 3	SEQ ID NO: 4	SEQ ID NO: :5	SEQ ID NO: 6	SEQ ID NO: 33	SEQ ID NO: 34
HLA-G-0039	SEQ ID NO: 9	SEQ ID NO: 10	SEQ ID NO: 11	SEQ ID NO: 12	SEQ ID NO: 13	SEQ ID NO: 14	SEQ ID NO: 15	SEQ ID NO: 16
HLA-G-0041	SEQ ID NO: 17	SEQ ID NO: 18	SEQ ID NO: 19	SEQ ID NO: 20	SEQ ID NO: 21	SEQ ID NO: 22	SEQ ID NO: 23	SEQ ID NO: 24
HLA-G-0090	SEQ ID NO: 25	SEQ ID NO: 26	SEQ ID NO: 27	SEQ ID NO: 28	SEQ ID NO: 29	SEQ ID NO: 30	SEQ ID NO: 31	SEQ ID NO: 32

Example 3**A) Binding of anti HLA-G antibodies to soluble human HLA-G, soluble degrafted human HLA-G with HLA-A specific sequence, human HLA-A2, and rat/ mouse H2-Kd**

5

Antibodies obtained from immunisation were screened for their binding properties to human, HLA-G, chimeric, degrafted HLA-G, HLA-A2 and rat/mouse H2-Kd. The respective assays are described below. For the testing of human HLA-G either monomeric, as well as dimeric and trimeric forms were used (see preparation below).

10 **Dimerization/Trimerization of human HLA-G MHC class I protein**

Supernatant containing monomeric His tagged soluble human HLA-G MHC class I protein (SEQ ID NO: 23) was loaded on to a HisTrap HP column (GE Healthcare #17-5248-02) with 5 ml Ni-Sepharose at the flow rate of 0,2ml/min overnight at room temperature using an ÄKTA-FPLC. Column was then washed with 2% DPBS containing 0.5M Imidazole (Merck #8.14223.025) until baseline was reached.

15

- 84 -

Column was then equilibrated with 10mM DTT in 2% DPBS containing 0.5M Imidazole and incubated for 30 min at room temperature. DTT was washed out from the column with PBS/10mM Imidazole and the protein was eluted at a gradient of 2 – 100% DPBS with 0.5mM Imidazole. After concentrating the eluate using Amicon-Ultra 15 M/Ultracel 10K, the protein was incubated for 24 hours at room temperature followed by 48 hours at 4°C to allow dimer/multimerization. Separation of the dimers and trimers was then performed using SEC in Superdex 200 HiLoad 16/60 (GE Healthcare #17-5175-01) and washed with 0.5M NaOH overnight. The column was equilibrated with PBS followed by saturation with 10mg/ml BSA. The dimers (fraction A9) and the trimers (fraction A8) were then collected, aliquoted and stored at -80°C till further use.

Human wt HLA-G binding ELISA

Streptavidin coated plates (Nunc, MicroCoat #11974998001) were coated with 25 µl/well biotinylated human wt HLA-G at a concentration of 250 ng/ml and incubated at 4°C overnight. After washing (3x90 µl/well with PBST-buffer) 25 µl anti-HLA-G samples (1:3 dilution in OSEP buffer) or reference antibody (G233, Thermo/Pierce #MA1-19449, 500 ng/ml) were added and incubated 1h at RT. After washing (3x90 µl/well with PBST-buffer) 25µl/well goat-anti-mouse H+L-POD (Biorad #170-6561, 1:2000 in OSEP) or donkey-anti-rabbit IgG POD (GE #NA9340V, 1:5000 in OSE) was added and incubated at RT for 1 h on shaker. For detection of rat IgGs a mixture of goat-anti-rat IgG1-POD (Bethyl #A110-106P), goat-anti-rat IgG2a-POD (Bethyl #A110-109P) and goat-anti-rat IgG2b-POD (Bethyl #A110-111P) 1:10000 in OSEP was added and incubated at RT for 1 h on shaker. After washing (6x90 µl/well with PBST-buffer) 25 µl/well TMB substrate (Roche, 11835033001) was added and incubated until OD 2–3. Measurement took place on a Tecan Safire 2 instrument at 370/492 nm.

Human degrafted HLA-G with HLA-A specific sequences binding ELISA

Streptavidin coated plates (Nunc, MicroCoat #11974998001) were coated with 25 µl/well biotinylated human degrafted HLA-G at a concentration of 250 ng/ml and incubated at 4°C overnight. After washing (3x90 µl/well with PBST-buffer) 25 µl anti-HLA-G samples (1:3 dilution in OSEP buffer) or rat serum (1:600 dilution in OSEP) were added and incubated 1h at RT. After washing (3x90 µl/well with PBST-buffer) 25µl/well of a mixture of goat-anti-rat IgG1-POD (Bethyl #A110-106P), goat-anti-rat IgG2a-POD (Bethyl #A110-109P) and goat-anti-rat IgG2b-POD

(Bethyl #A110-111P) 1:10000 in OSEP was added and incubated at RT for 1 h on shaker. After washing (6x90 µl/well with PBST-buffer) 25 µl/well TMB substrate (Roche, 11835033001) was added and incubated until OD 2 – 3. Measurement took place on a Tecan Safire 2 instrument at 370/492 nm.

5 **Rat MHC I (RT1-A) binding ELISA**

Streptavidin coated plates (Nunc, MicroCoat #11974998001) were coated with 25 µl/well biotinylated rat MHC I (RT1-A) at a concentration of 250 ng/ml and incubated at 4°C overnight. After washing (3x90 µl/well with PBST-buffer) 25 µl anti-HLA-G samples (1:3 dilution in OSEP buffer) or rat serum (1:600 dilution in OSEP) were added and incubated 1h at RT. After washing (3x90 µl/well with PBST-buffer) 25µl/well of a mixture of goat-anti-rat IgG1-POD (Bethyl #A110-106P), goat-anti-rat IgG2a-POD (Bethyl #A110-109P) and goat-anti-rat IgG2b-POD (Bethyl #A110-111P) 1:10000 in OSEP was added and incubated at RT for 1 h on shaker. After washing (6x90 µl/well with PBST-buffer) 25 µl/well TMB substrate (Roche, 11835033001) was added and incubated until OD 2 – 3. Measurement took place on a Tecan Safire 2 instrument at 370/492 nm.

HLA-A2 binding ELISA

Streptavidin coated plates (Nunc, MicroCoat #11974998001) were coated with 25 µl/well **biotinylated human HLA-A2** at a concentration of 250 ng/ml and incubated at 4°C overnight. After washing (3x90 µl/well with PBST-buffer) 25 µl anti-HLA-G samples (1:3 dilution in OSEP buffer) or rat serum (1:600 dilution in OSEP) were added and incubated 1h at RT. After washing (3x90 µl/well with PBST-buffer) 25µl/well of a mixture of goat-anti-rat IgG1-POD (Bethyl #A110-106P), goat-anti-rat IgG2a-POD (Bethyl #A110-109P) and goat-anti-rat IgG2b-POD (Bethyl #A110-111P) 1:10000 in OSEP was added and incubated at RT for 1 h on a shaker. After washing (6x90 µl/well with PBST-buffer) 25 µl/well TMB substrate (Roche, 11835033001) was added and incubated until OD 2 – 3. Measurement took place on a Tecan Safire 2 instrument at 370/492 nm.

Binding kinetics of anti-HLA-G antibodies

30 Binding kinetics of anti-HLA-G antibodies to human HLA-G, human HLA-G degrafted and human HLA-A2 were investigated by surface plasmon resonance using a BIACORE T200 instrument (GE Healthcare). All experiments were performed at 25°C using PBS Buffer (pH 7.4 + 0.05% Tween20) as running buffer

- 86 -

and PBS Buffer (+ 0,1% BSA) as dilution buffer. Anti-human Fc (JIR009-005-098, Jackson) or anti-rat Fc (JIR112-005-071, Jackson) or anti-Mouse Fc (JIR115-005-071, Jackson) antibodies were immobilized on a Series S CM5 Sensor Chip (GE Healthcare) at pH 5.0 by using an amine coupling kit supplied by GE Healthcare.

5 Anti-HLA-G antibodies were captured on the surface leading to a capturing response of 50 – 200 RU. HLA-G molecules were injected for 180 s at 30 μ l/min with concentrations from 2.5 up to 800 nM (2x1:2 and 4x1:3 dilution series) onto the surface (association phase). The dissociation phase was monitored for 300 -600 sec by washing with running buffer. The surface was regenerated by injecting H3PO4 (0,85%) for 60 + 30 seconds for anti-human Fc capturing antibodies, glycine pH1,5 for 60 seconds and glycine pH2,0 for 60 seconds for anti-rat Fc capturing antibodies, H3PO4 (0,85%) for 80 + 60 seconds for anti-mouse Fc capturing antibodies. Bulk refractive index differences were corrected by subtracting the response obtained from a mock surface. Blank injections were subtracted (double referencing). The

10 derived curves were fitted to a 1:1 Langmuir binding model using the BIAevaluation software.

15

Cross-blocking of anti-HLA-G antibodies

Cross-blocking experiments of anti-HLA-G antibodies binding to human HLA-G were investigated by surface plasmon resonance using a BIACORE T200 or B4000 instrument (GE Healthcare). All experiments were performed at 25°C using PBS Buffer (pH 7.4 + 0.05% Tween20) as running buffer.

20

Anti-human Fab (GE-Healthcare, 28-9583-25) antibodies were immobilized on a Series S CM5 Sensor Chip (GE Healthcare) according to the protocol of the provider, to capture antibodies from OMT rats that contain a human Ck Domain. Anti-HLA-G antibodies were captured for 70s at a concentration of 15 μ g/ml. Wt HLA-G was injected (30 μ l/min) at a concentration of 500 or 1000 nM for 60 seconds. Wt rat-antibody was then injected for 90 seconds at a concentration of 30 μ g/ml. The dissociation phase was monitored for 60 or 240 sec by washing with running buffer. The surface was regenerated by injecting Glycine pH 1,5 for 60 seconds and an

25

30 additional stabilization period of 90 sec.

In another assay setup, Anti-human Fab (GE-Healthcare, 28-9583-25) antibodies were immobilized on a Series S CM5 Sensor Chip (GE Healthcare) according to the protocol of the provider, to capture antibodies from OMT rats that contain a human Ck Domain. Anti-HLA-G antibodies were captured for 90s at a concentration of 30

- 87 -

5 $\mu\text{g/ml}$. Unoccupied binding sites on the capture antibodies were blocked by 4 x 120 sec. injection of human IgG (JIR009-000-003) at a concentration of 500 $\mu\text{g/ml}$ and a flow rate of 30 $\mu\text{l/min}$. Wt HLA-G was injected (30 $\mu\text{l/min}$) at a concentration of 500 nM for 90 seconds. The second antibody from OMT rats (human Ck Domain) was then injected for 90 seconds at a concentration of 30 $\mu\text{g/ml}$. The dissociation phase was monitored for 240 sec by washing with running buffer. The surface was regenerated by injecting Glycine pH 1,5 for 60 seconds and an additional a stabilization period of 90 sec.

10 **Table: Binding of HLA-G antibodies to recombinant soluble HLA-G MHC class 1 complex, in its monomeric, dimeric and trimeric form (ELISA)**

antibody	HLA-G Monomer EC50 [nM]	HLA-G Dimer EC50 [nM]	HLA-G Trimer EC50 [nM]
HLA-G-0031	7.19	1.87	1.86
HLA-G-0039	7.35	4.10	5.29
HLA-G-0041	4.95	5.31	4.87
HLA-G-0090	n.a.	n.a.	n.a.

15 The above table summarizes the binding of different rat anti-human HLA-G monoclonal antibodies, derived from wt protein IMS. Shown are the relative EC50 values [ng/ml] of the respective binding to rec. wt monomeric, dimeric and trimeric HLA-G proteins as assessed by ELISA. The ELISA was set up by coating the biotinylated wt HLA-G antigen to strepdavidin plates. After incubation and washing steps, the respective antibodies were bound in a concentration range from 10 – 0 μg in 1:2 dilution steps. Detection of bound antibodies was carried out by anti-Fc-antibody-POD conjugates. EC50 values were determined from the resulting binding curves at the antibody concentrations generating the half-maximal signal. In case of the non-biotinylated HLA-G dimer and trimer antigens, immobilization was carried out by random coating on assay plates.

20

25

HLA-G wt versus HLA-G degraft binding ELISA:

Anti-body	wt HLA-G (SEQ ID NO:43) (monomer)		HLA-A consensus on HLA-G degraft (SEQ ID NO:44)	
	EC50 rel [ng/ml]	Max. OD	EC50 rel [ng/ml]	Max. OD
HLA-G-0031	7.19	1.6	-	0.13
HLA-G-0039	7.35	1.4	-	0.13
HLA-G-0041	8.60	2.3	-	0.15
HLA-G-0090	10.37	3.4	-	0.2

The above table summarizes the binding of different rat anti-human HLA-G monoclonal antibodies, derived from wt protein IMS both of wt as well as OMT rats. Shown are the relative EC50 values [ng/ml] and maximal OD of the respective binding to rec. wt monomeric HLA-G protein or the so-called grafted HLA-G (HLA-A consensus sequence on HLA-G backbone) protein as assessed by ELISA. The ELISA was set up by coating the biotinylated wt HLA-G or consensus antigen to streptavidin plates. After incubation and washing steps, the respective antibodies were bound in a concentration range from 10 – 0 µg in 1:2 dilution steps. Detection of bound antibodies was carried out by anti-Fc-antibody-POD conjugates. EC50 values were determined from the resulting binding curves at the antibody concentrations generating the half-maximal signal.

HLA-G wt versus HLA-G degraft binding – Surface plasmon resonance
Binding affinities for HLA-G antibodies to recombinant HLA-G (SEQ ID NO :43) and control modified human HLA-G β2M MHC class I complex (wherein the HLA-G specific amino acids have been replaced by HLA-A consensus amino acids (= degrafted HLA-G SEQ ID NO: 44:)) (“-“ indicates no detectable binding)

Anti-body	wt HLA-G (SEQ ID NO:25) (monomer)				HLA-A consensus on HLA-G degraft (SEQ ID NO:26)			
	ka (1/Ms)	kd (1/s)	t 1/2 (min)	KD (M)	ka (1/Ms)	kd (1/s)	t 1/2 (min)	KD (M)
HLA-G-0031	4.9E+04	3.7E-03	3	7.5E-08	-	-	-	-
HLA-G-0031-0104 (humanized)	8,3E+04	2,0E-03	6	2,4E-08				
HLA-G-0039	4.6E+05	4.4E-04	27	9.5E-10	-	-	-	-
HLA-G-0041	3.8E+05	4.9E-04	23	1.3E-09	-	-	-	-
HLA-G-0090	2.3E+05	8.5E-04	14	3.6E-09	-	-	-	-

The above table summarizes the antibody affinities and t1/2 values against wt and degrafted HLA-G as assessed by Surface plasmon resonance (Biacore) analysis.

Binding kinetics of anti-HLA-G antibodies to human HLA-G and human HLA-G degrafted were investigated by surface plasmon resonance using a BIACORE T200 instrument (GE Healthcare). All experiments were performed at 25°C using PBS Buffer (pH 7.4 + 0.05% Tween20) as running buffer and PBS Buffer (+ 0,1% BSA) as dilution buffer. Anti-human Fc (JIR009-005-098, Jackson) or anti-rat Fc (JIR112-005-071, Jackson) or anti-Mouse Fc (JIR115-005-071, Jackson) antibodies were immobilized on a Series S CM5 Sensor Chip (GE Healthcare) at pH 5.0 by using an amine coupling kit supplied by GE Healthcare. Anti-HLA-G antibodies were captured on the surface leading to a capturing response of 50 – 200 RU. Non-biotinylated HLA-G molecules were injected for 180 s at 30 µl/min with concentrations from 2.5 up to 800 nM (2x1:2 and 4x1:3 dilution series) onto the surface (association phase). The dissociation phase was monitored for 300 -600 sec

by washing with running buffer. The surface was regenerated by injecting H₃PO₄ (0,85%) for 60 + 30 seconds for anti-human Fc capturing antibodies, glycine pH1,5 for 60 seconds and glycine pH2,0 for 60 seconds for anti-rat Fc capturing antibodies, H₃PO₄ (0,85%) for 80 + 60 seconds for anti-mouse Fc capturing antibodies. Bulk refractive index differences were corrected by subtracting the response obtained from a mock surface. Blank injections were subtracted (double referencing). The derived curves were fitted to a 1:1 Langmuir binding model using the BIAevaluation software (- in the table above indicates that no binding could be detected).

In a further experiment the following reference antibodies (obtained from different commercial vendors) were compared for binding to monomeric human HLA-G MHC I (SEQ ID NO: 43 (“HLA-G-0003”)) and “degrafted” human HLA-G with consensus HLA-A specific positions (SEQ ID NO: 44 (“HLA-G-0007”)):

MEM/G9, 87G, G233, 2A12, 4H84, 5A6G7, 6D463, 9-1F10, MEM-G/1, MEM-G/11, MEM-G/2 and MEM-G/4 (“-“ indicates no detectable binding).

Antigen	Antibody	ka (1/Ms)	kd (1/s)	t 1/2 (Min)	KD (M)
wt HLA-G (SEQ ID NO:43) (monomer)	MEM/G9	1.5E+05	1.1E-03	10	7.7E-09
	87G	-	-	-	-
	G233	1.8E+05	3.7E-03	3	2.0E-08
	2A12	-	-	-	-
	4H84	-	-	-	-
	5A6G7	-	-	-	-
	6D463	-	-	-	-
	9-1F10	-	-	-	-
	MEM-G/1	-	-	-	-
	MEM-G/11	7.4E+04	8.5E-04	14	1.2E-08
	MEM-G/2	-	-	-	-
	MEM-G/4	-	-	-	-

Antigen	Antibody	ka (1/Ms)	kd (1/s)	t 1/2 (Min)	KD (M)
HLA-A consensus on HLA-G degraft (SEQ ID NO:44)	MEM/G9	1.2E+05	3.6E-02	0.3	3.0E-07
	87G	-	-	-	-
	G233	-	-	-	-
	2A12	-	-	-	-
	4H84	-	-	-	-
	5A6G7	-	-	-	-
	6D463	-	-	-	-
	9-1F10	-	-	-	-
	MEM-G/1	-	-	-	-
	MEM- G/11	8.9E+04	1.2E-03	10	1.3E-08
	MEM-G/2	-	-	-	-
	MEM-G/4	-	-	-	-

5 Interestingly, most of the measured antibodies did not show any specific binding to monomeric human HLA-G MHC I (SEQ ID NO: 43 (“HLA-G-0003”)) including also antibody 87G. The binding to oligomeric forms of HLA-G as described in literature might be avidity driven due to the increased binding sites of oligomeric forms.

10 Only antibody MEM/G9 with a KD value of the binding affinity of $7.7E^{-09}M$, antibody G233 with a KD value of $2.0E^{-08} M$ and MEM-G/11 with a KD value of the binding affinity of $1.2E^{-08} M$ showed binding to monomeric wt human HLA-G MHC I complex. However, one of these antibodies MEM-G/11 also showed some binding/crossreactivity to HLA-A consensus on HLA-G degraft (SEQ ID NO:44). In addition, another antibody (MEM/G9) also showed stronger unspecific binding to HLA-A consensus on HLA-G degraft (SEQ ID NO:44).

Example 4

15 a) Receptor binding inhibition (with mono-, di- and trimeric HLA-G): ILT-2 and ILT-4 blocking ELISA

20 Streptavidin coated plates (Nunc, MicroCoat #11974998001) were coated with 25 μ l/well biotinylated human wt HLA-G at a concentration of 500-1000 ng/ml and incubated at 4°C overnight. After washing (3x90 μ l/well with PBST-buffer) 25 μ l anti-HLA-G samples were added in decreasing concentrations starting at 10 or 3 μ g/ml, then diluted in 1:3 or 1:2 steps and incubated 1h at RT. After washing (3x90

- 92 -

5 μ l/well with PBST-buffer) 25 μ l/well c-myc-tagged recombinant ILT-2 receptor was added at a concentration of 200 ng/ml and incubated for 1 h at room temperature. After washing (3x90 μ l/well with PBST-buffer) 25 μ l/well goat-anti-c-myc-POD (Bethyl #A190-104P 1:7000 in PBST + 0.5% BSA) or anti humanFc γ POD (JIR, 109-036-098, 1:8000 in PBST + 0.5% BSA) was added and incubated at RT for 1 h on a shaker. After washing (3x90 μ l/well with PBST-buffer), 25 μ l/well TMB substrate (Roche, 11835033001) was added and incubated until OD 2 – 3. Measurement took place on a Tecan Safire 2 instrument at 370/492 nm.

Candidate	% inh. ILT2 (3 μ g/ml antibody)	% inh. ILT4 (3 μ g/ml antibody)
HLA-G-0031	72.8	39.8
HLA-G-0039	14.0	23.9
HLA-G-0041	17.4	18.4
HLA-G-0090	100	Not tested

10

The table above summarizes the extent of ILT-2 and ILT-4 blocking of different antibodies bound to HLA-G at a concentration of 3 μ g/ml, relative to an HLA-G:receptor interaction that is not blocked. HLA-G-0090 was tested in a separate experiment for ILT2 blockade, ILT4 blocking was not assessed.

15 **b) Biochemical comparison of anti-HLA-G antibodies for their ILT2 and -4 binding inhibition properties using a different assay set-up**

20 The ELISA was set up by coating the Fc tagged ILT2 and ILT4 respectively to Maxisorp microtiter plates. After incubation and washing steps, the respective antibodies were added at a concentration of 100nM. Soluble His tagged monomeric, dimeric or trimeric HLA-G was added to the wells. After incubation and washing steps, detection of bound receptor was carried out by anti-His-antibody-POD conjugates. Percentage inhibition (%) was calculated in comparison to values obtained from wells with ILT2/4 + HLA-G (mono-, di-, or Trimer) without anti HLA-G or ILT2/4 antibodies (100% binding = 0% inhibition).

Antibody	% inhibition of ILT2 binding			% inhibition of ILT4 binding		
	Monomer	Dimer	Trimer	Monomer	Dimer	Trimer
HLAG-0031	101	99	100	17	54	68
HLAG-0039	-450	25	70	-224	-105	-43
HLAG-0041	-437	23	67	-184	-113	-39
HLAG-0090*	92	100	99	31	31	47
MEM-G/9	-442	1	4	-14	-44	-40
87G	-49	19	29	13	18	14
G233	12	-132	3	-898	-20	58
anti-ILT2/ILT4	113	100	101	44	60	60

The above tables summarize the blocking of interaction between rec. HLA-G proteins (monomer and oligomers) to its receptors ILT2 and ILT4 by the described HLAG antibodies at a concentration of 110nM (*HLAG-0090 was tested at a concentration of 44nM) as assessed by ELISA. Shown are the % inhibitions of the HLA-G/receptor interaction (for ILT2 and ILT4). The less pronounced ILT4 inhibition depends on the major β 2M dependent interaction of this receptor.

The bar graphs in Figures 4a and b show % inhibition achieved by the described anti-HLA-G antibodies in comparison to commercially available antibodies. Commercially available HLA-G antibodies 87G, MEM/G09 and G233 do not block HLA-G / ILT2 or ILT4 interaction as efficiently as the described antibodies. Further, the commercially available antibodies lead to increased binding of HLA-G to ILT2 or ILT4 upon binding in some cases.

c) Inhibition of CD8a binding to HLAG by anti-HLAG antibodies

Streptavidin coated 384 well plates were blocked with 30 μ l/well of blocking solution. Blocking solution prepared by diluting 5% Polyvinylalcohol (PVA, Sigma #P8136) and 8% Polyvinylpyrrolidone (PVP, Sigma #PVP360) 1:10 in Starting block T20 (Thermo Scientific #37543) by adding 3.5 ml PVA + 3.5 ml and PVP to 35 ml Starting Block T20. 30 μ l of Biotinylated HLAG (3 μ g/ml) diluted in blocking solution were added to each well and incubated at room temperature for 1 hour on a shaker. Wells were washed 3 times with 100 μ l of PBS (PAN Biotech # P04-36500) containing 0.1% Tween-20 (Merck #8.22184.500). The wells were then incubated with 30 μ l of anti-HLAG antibodies diluted in blocking buffer in triplicates for 1 hour at room temperature on a shaker and then washed 3 times with 100 μ l of PBS

- 94 -

containing 0.1% Tween-20. Recombinant CD8a (Sino Biological #10980-H08H, reconstituted at stored for 1 week at 4°C) was diluted in blocking solution (1.25µg/ml), and 30µl were added to all the wells and incubated for 2 hours at room temperature on a shaker. Wells were washed 3 times with 100µl of PBS containing
5 0.1% Tween-20. HRP conjugated polyclonal anti-CD8a rat IgG antibody (USBiological #033547-HRP) was diluted in 3% Bovine Serum Albumin Fraction V (Roche #10735086001)/ PBS 0.2% Tween20 and 30µl of this dilution was added to each well. The plate was then incubated for 1 hour at room temperature on a shaker and washed 3 times with 100µl of PBS containing 0.1% Tween-20. 30µl of TMB
10 substrate (BM-Blue, soluble HRP substrate, Roche #11484281001) was then added to each well followed by 25 minutes of incubation at room temperature on a shaker. The reaction was then stopped by adding 25µl of sulfuric acid to each well and the absorbance as measured at 450 nM in a plate reader. Specific binding of CD8a to HLAG was calculated by subtracting the average of the background values form the
15 average of the binding values. Total binding of CD8 to HLAG in the absence of antibodies was considered 100% binding or 0% inhibition.

The bar graph in Figures 4c shows % inhibition achieved by the described anti-HLA-G antibodies in comparison to commercially available antibodies. Commercially available HLA-G antibodies 87G does not block HLA-G / CD8a interaction where
20 as MEM/G09 and G233 partially inhibit HLAG interaction with CD8a compared to described antibodies in this set up.

Example 5

Binding of anti HLA-G antibodies to cells

25 a) Cell-surface HLA-G binding ELISA

25 µl/well of JEG3 cells (naturally expressing HLA-G, 20000 cells/well), Skov-3 cells or Skov-3 cells expressing recombinant HLA-G on the cell surface (both 10000 cells/well) were seeded into tissue culture treated 384-well plates (Corning, 3701) and incubated at 37°C overnight. The next day 12.5 µl of anti-HLA-G samples (final
30 dilution 1:3) were added and incubated for 2h at 4°C. Cells were fixed by addition of 50 µl/well glutaraldehyde to a final concentration of 0,05% (Sigma Cat.No: G5882; Lot No.: 056K5318). After washing (3x90 µl/well with PBST-buffer) 25µl/well goat-anti-mouse H+L-POD (Biorad #170-6561 1:2000 in OSEP) or donkey-anti-rabbit IgG POD (GE #NA9340V, 1:5000 in OSE) was added and
35 incubated at RT for 1 h on shaker. For detection of rat IgGs a mixture of goat-anti-

rat IgG1-POD (Bethyl #A110-106P), goat-anti-rat IgG2a-POD (Bethyl #A110-109P) and goat-anti-rat IgG2b-POD (Bethyl #A110-111P) 1:10000 in OSEP was added and incubated at RT for 1 h on shaker. After washing (4x90 μ l/well with PBST-buffer) 25 μ l/well TMB substrate (Roche, 11835033001) was added and incubated until OD 2 – 3. Measurement took place on a Tecan Safire 2 instrument at 370/492 nm.

Antibody	Jeg3	wt Skov3	HLA-G ⁺ Skov3	wt PA-TU-8902	HLA-G ⁺ PA-TU-8902
HLA-G-0031	+++	-	+++	-	+++
HLA-G-0039	+++	+	+++	-	+++
HLA-G-0041	+++	++	+++	-	+++
HLA-G-0090	+++	-	+++	-	+++

The above table summarizes the binding of different rat anti-human HLA-G monoclonal antibodies to HLA-G expressed on different cells and cell lines as assessed by FACS analysis. Either the binding to naturally HLA-G expressing JEG3 tumor cells or Skov3 or PA-TU-8902 transfectants and respective parental, untransfected cells is described.

b) Binding of HLA-G antibodies to natural or recombinant HLA-G expressed on cells (as assessed by FACS analysis)

For flow cytometry analysis, cells were stained with anti HLA-G mAbs at 4°C. Briefly, 25 μ l/well of each cell suspension (5x10⁴ cells/well) was transferred into a polypropylene 96-Well V-bottom plate and prechilled in the fridge at 5°C for 10 min. Anti-HLA-G samples were diluted in staining buffer to a 2-fold starting concentration of 80 μ g/ml. A 4-fold serial dilution of the antibodies was performed and 25 μ l/well of the antibody solution was added to the prepared cells and incubated for 1h at 5°C. Cells were washed twice with 200 μ l/well staining buffer and centrifugation at 300g for 3min. For detection fluorescent labeled anti-species antibody (goat anti rat IgG (H+L) conjugated to Alexa 488, Life technologies # A11006; or goat anti-mouse IgG (H+L), Life technologies # A11001) or goat anti-human IgG (H+L) conjugated to Alexa 488, Life technologies # A11013) was diluted to 20 μ g/ml in staining buffer and cell pellets were resuspended in 50 μ l/well

detection antibody. After a 1 hour incubation at 5°C cells were again washed twice with staining buffer, resuspended in 70µl of staining buffer and measured at a FACS Canto II.

5 An exemplary FACS staining for anti-HLA-G antibodies HLA-G 0031, HLAG 0039, HLA-G 0041 and HLA-G 0090 is given in the FACS overlays of Figure 4:

Example 6

Anti HLA-G antibodies inhibit/modulate the binding of ILT2 to HLA-G expressed on JEG3 cells

10 For analysis, JEG3 cells (ATCC HTB36) were stained with ILT2-Fc fusion proteins (control = no inhibition) with or without pre-incubation with different anti-HLA-G antibodies. For the pre-incubation with anti-HLA-G antibodies 25µl/well of the cell suspension was transferred into a polypropylene 96-Well V-bottom plate and prechilled in the at 4°C for 10min. Anti HLA-G antibodies or reference antibodies
15 (G233, MEM-G/9 or 87G) were diluted in staining buffer to a 2-fold concentration of 80µg/ml and 25µl/well of the antibody solution was added to the prepared cells and incubated for 1h at 5°C. Cells were washed twice with 200µl/well staining buffer with centrifugation at 300g for 3min and finally resuspended in 25µl/well staining buffer.

20 The detection of human ILT2-Fc Chimera protein (RD #2017-T2-050) to a) JEG3 cells pre-incubated anti HLA-G mAb or b) untreated JEG3 cells as reference was determined as follows: Briefly, the ILT2-Fc or control human IgG (Jackson-Immuno-Research # 009-000-003) were diluted in staining buffer to a 2-fold concentration of 20µg/ml (ILT2) and 25µl/well of the ILT2-Fc protein solution was
25 added to the prepared cells and incubated for 2h at 5°C. Cells were again washed twice with 200µl/well staining buffer the human ILT2-Fc protein was detected with fluorescent labeled anti human IgG Fc-gamma specific antibody (F(ab')₂ Fragment Goat Anti-Human IgG, Fcγ fragment specific-FITC, Jackson-Immuno-Research # 109-096-008) at a dilution of 10µg/ml in staining buffer. Cell pellets were
30 resuspended in 50µl/well detection antibody. After a 1-hour incubation at 5°C cells were washed twice with staining buffer, resuspended in 70µl and measured at a FACS Canto II to determine ILT2 binding to JEG 3 cells.

As control, the anti-HLA-G antibodies bound to JEG-3 pre-incubated cells were detected by using anti-species antibody (goat anti-rat IgG (H+L) conjugated to Alexa

488, (Life technologies # A11006), or goat-anti mouse IgG (H+L)-Alexa 488, (Life technologies, # A11001) at a concentration of 10µg/ml.

5 The graph in Figure 5 shows the respective ability of different HLA-G antibodies to modify the interaction and binding of recombinant ILT2 to HLA-G naturally expressed on JEG3 tumor cells.

10 The following table summarizes the results from the experiments. The binding of the anti-HLA-G antibodies to JEG3 cells is depicted as + = weak binding - +++=strong binding. The ability of the anti-HLA-G antibodies either to inhibit/block or increase the binding of ILT2 to the HLA-G expressing JEG3 cells. In the last column, the binding of the recombinant ILT2 to the cells or the inhibition/blockade thereof is shown/quantified (staining of ILT2-Fc in the absence of an anti-HLA-G antibody was set to 100% binding which 0% inhibition, a negative value indicates an even increased binding; staining signal differences below 5% were not significant as categorizes with no effect):

Antibody	Binding on JEG-3 cells	HLA-G:ILT2 interaction	Inhibition of ILT2 binding to Jeg3 cells
no mAb (ctrl)	-	-	0% inhibition =100% binding
HLA-G-0031	+++	inhibits binding of ILT2	95.1 % inhibition
HLA-G-0039	+++	increased binding of ILT2	-72,9 % (=increase/stimulation of ILT2 binding)
HLA-G-0041	+++	increased binding of ILT2	-76,7 % (=increase/stimulation of ILT2 binding)
HLA-G-0090	+++	inhibits binding of ILT2	91.8 % inhibition
87G	++	no significant effect	2.3 % inhibition
MEM-G/9	+++	inhibits binding of ILT2	-27.9 % (=increase/stimulation of ILT2 binding)
G233	+++	inhibits binding of ILT2	-55.8% (=increase/stimulation of ILT2 binding)

Example 7**Monocyte Cytokine restoration assay (after HLA-G mediated suppression)**

5 The following co-culture assay of HLA-G-expressing cells with Monocytes was used for the functional characterization of the different rat anti-human HLA-G monoclonal antibodies. Peripheral human Monocytes were isolated from blood of healthy donors. Briefly, blood was collected in tubes containing an anticoagulant agent and diluted 1:2 in PBS. To isolate peripheral blood mononuclear cells (PBMCs) 30ml of the mixture was transferred to each Leucosep tube with prefilled
10 separation medium. The PBMC specific band was collected after 12min centrifugation (1200xg without brake), washed three times with PBS and centrifuged for 10min at 300xg. Finally, cell pellets were resuspended in MACS buffer from Miltenyi and human monocytes were isolated from the PBMCs via magnetic separation with the human Monocyte Isolation Kit II from Miltenyi (#130-091-153)
15 according to the manufacturer's instructions (negative selection). The isolated monocytes were resuspended in primary cell culture medium (RPMI 1640, PAN #P04-17500 supplemented with 10% FCS, Gibco #10500; 2mM L-glutamine, Sigma #G7513; 1mM Sodium Pyruvate, Gibco #11360; MEM Non-Essential Amino Acids, Gibco #11140; 0,1mM 2-Mercaptoethanol, Gibco #31350; MEM Vitamins, Gibco #11120; Penicillin Streptomycin, Gibco #15140) at a density of 5x10⁵ cells/ml. The enrichment of CD14⁺ CD16⁺ cells was monitored by flow cytometry and ILT2 and ILT4 expression of the cells was analyzed. For the co-culture assay of the enriched monocytes with HLA-G-expressing cells, JEG-3 cells ((ATCC HTB36) were seeded one day prior to the assay in a 96-well-flat bottom tissue culture plate with 8x10³
20 cells/well in 100µl in JEG-3 culture medium (MEM Eagle with EBSS and L-glutamine, PAN #P04-00509 supplemented with 10% FCS, Gibco #10500; 1mM Sodium Pyruvate, Gibco #11360; MEM Non-Essential Amino Acids Gibco #11140) to form a confluent layer on the day of the assay. . In some experiments a JEG-3 HLAG knockout cell line was used and seeded as the JEG-3 wt cells as described
25 above. The adherent JEG-3 cells were pre-incubated with a 4fold serial dilution of anti HLA-G antibodies in primary cell culture medium. Therefore the supernatant from the adherent JEG-3 cells was removed and 50µl/Well of the prepared antibody solution was added and incubated at 37°C and 5% CO₂ in a humidified atmosphere for 1h. Human monocytes were added to the anti HLA-G antibodies pre-incubated
30 JEG-3 cells with 2,5x10⁴ human monocytes / Well in 50µl primary cell culture medium and co-culture was incubated at 37°C and 5% CO₂ in a humidified atmosphere overnight (approx. 18-20 hours). On the next day a LPS stimulation with

- 100 -

From above table it becomes clear that the antibodies of the present invention were able to induce a TNF alpha release in monocytes coculture with HLA-G expressing JEG-3 cells, while they were not able to induce a TNF alpha release in monocytes cocultured with JEG-3 cells with a HLA-G knock-out.

- 5 From the table it becomes clear that the reference antibodies are not truly HLA-G specific, as they induce strong TNF alpha release also in HLA-G knock out cell lines.

Dependent on the donor (different donor below) the percentage % TNF release (restoration) varies.

10

Cell line	JEG-3 wild type (wt)	JEG-3 wild type (wt)	JEG-3 wild type (wt)
Anti-HLA-G antibody	HLAG-0090	HLAG-0031	HLAG-0041
40 µg/ml	214%	77%	
10 µg/ml	221%	74%	40%
2,5 µg/ml	233%	67%	59%
0,63 µg/ml	219%	44%	66%
0,16 µg/ml	198%	14%	44%
untreat	0%	0%	0%
Monocytes only	100%	100%	100%

Patent Claims

1. An isolated antibody that bind to human HLA-G; and that inhibits ILT2 binding to HLAG on JEG-3 cells (ATCC HTB36) and restores HLA-G specific suppressed TNF alpha release by monocytes co-cultured with JEG-3 cells.
- 5 2. An isolated antibody that bind to human HLA-G wherein the antibody comprises
 - 10 A) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:1, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:2, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:3; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:4; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:5 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:6; or
 - 15 B) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:9, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:10, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:11; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:12; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:13 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:14; or
 - 20 C) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:17, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:18, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:19; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:20; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:21 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:22; or
 - 25 D) (a) a VH domain comprising (i) HVR-H1 comprising the amino acid sequence of SEQ ID NO:25, (ii) HVR-H2 comprising the amino acid sequence of SEQ ID NO:26, and (iii) HVR-H3 comprising an amino acid sequence selected from SEQ ID NO:27; and (b) a VL domain comprising (i) HVR-L1 comprising the amino acid sequence of SEQ ID NO:28; (ii) HVR-L2 comprising the amino acid sequence of SEQ ID NO:29; and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30; or
- 30

- 102 -

acid sequence of SEQ ID NO:29 and (iii) HVR-L3 comprising the amino acid sequence of SEQ ID NO:30.

3. The antibody according to claim 2, wherein the antibody comprises

A)

5 iv) comprises a VH sequence of SEQ ID NO:7 and a VL sequence of SEQ ID NO:8;

v) or humanized variant of the VH and VL of the antibody under i); or

vi) comprises a VH sequence of SEQ ID NO:33 and a VL sequence of SEQ ID NO:34; or

10 B)

comprises a VH sequence of SEQ ID NO:15 and a VL sequence of SEQ ID NO:16; or

C)

15 comprises a VH sequence of SEQ ID NO:23 and a VL sequence of SEQ ID NO:24; or

D)

comprises a VH sequence of SEQ ID NO:31 and a VL sequence of SEQ ID NO:32.

4. An isolated antibody that binds to human HLA-G, wherein the antibody

20 a) binds to the same epitope as an antibody which comprises a VH sequence of SEQ ID NO:7 and a VL sequence of SEQ ID NO:8;

or b) binds to the same epitope as an antibody which comprises a VH sequence of SEQ ID NO:31 and a VL sequence of SEQ ID NO:32.

25 5. The anti-HLA-G antibody according to any one of claims 1 to 4, wherein the antibody

- 103 -

- a) does not crossreact with a modified human HLA-G β 2M MHC I complex comprising SEQ ID NO:44; and/ or
- b) does not crossreact with human HLA-A2 β 2M MHC I complex comprising SEQ ID NO:39 and SEQ ID NO: 37; and/ or
- 5 c) does not crossreact with a mouse H2Kd β 2M MHC I complex comprising SEQ ID NO:45; and/ or
- d) does not crossreact with rat RT1A β 2M MHC I complex comprising SEQ ID NO:47; and/ or
- 10 e) inhibits ILT2 binding to monomeric HLA-G β 2M MHC I complex; and/or
- f) inhibits ILT2 binding to trimeric HLA-G β 2M MHC I complex; and/or
- g) inhibits ILT2 binding to monomeric and/or dimeric and/or trimeric HLA-G β 2M MHC I complex by more than 50%; and/ or
- h) inhibits ILT2 binding to JEG3 cells (ATCC No. HTB36); and/or
- 15 i) binds to (HLA-G on) JEG3 cells (ATCC No. HTB36), and inhibits ILT2 binding to (HLA-G on) JEG3 cells (ATCC No. HTB36) ; and/or
- j) inhibits CD8a binding to HLAG by more than 80%.
6. The antibody according to any one of the preceding claims, wherein the antibody is of IgG1 isotype.
- 20 7. The antibody according claim 6, wherein the antibody is of IgG1 isotype with mutations L234A, L235A and P329G (numbering according to the EU index of Kabat).
8. Isolated nucleic acid encoding the antibody according to any one of the preceding claims.
- 25 9. A host cell comprising the nucleic acid of claim 8.
10. A method of producing an antibody comprising culturing the host cell of claim 8 so that the antibody is produced.

- 104 -

11. The method of claim 10, further comprising recovering the antibody from the host cell.
12. A pharmaceutical formulation comprising the antibody according any one of claims 1 to 7 and a pharmaceutically acceptable carrier.
- 5 13. The antibody according any one of claims 1 to 7 for use as a medicament.
14. The antibody according any one of claims 1 to 7 for use in treating cancer.
15. Use of the antibody according any one of claims 1 to 7 in the manufacture of a medicament.

Fig. 1




Fig. 2A




Fig. 2B




Fig. 3A




Fig. 3B




Fig. 3C




Fig. 4A




Fig. 4B




Fig. 4C




Fig. 4D




Fig. 5A




Fig. 5B




Fig. 6A




Fig. 6B




Fig. 6C




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11




Fig. 11




Fig. 11




Fig. 3A

